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Airway inflammation in asthma and allergic rhinitis share common 
characteristics, and these conditions can be seen as manifestations 
of one disease. The aim was to investigate airway inflammation 
biomarkers in the light of this view.
We dected differences in microRNA expression in the nasal mucosa 
of asthma and allergic rhinitis patients when no significant 
differences in the inflammatory cells and cytokines were found. 
A biomarker was found in the sputum of the asthmatic patients, 
and this marker was also detected in the nasal lavage fluid of these 
patiens. 
Our results suggest that new sensitive biomarker panels for the 
clinical evaluation of allergic airway inflammation may be found 
using miRNA analysis and proteomics. Upper airways could be 
used as a surrogate of lower airways when assessing airway 
inflammation in asthma.
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7AbStRAct 
The prevalence of chronic rhinitis and asthma in the adult population is 
high worldwide. These diseases often coexist; the vast majority of asth-
matics have rhinitis and many patients with rhinitis also have asthma. 
The upper and lower airway inflammation in allergic rhinitis and asthma 
have several common characteristics. Thus, rhinitis and asthma can be 
seen as manifestations of one disease with a common underlying inflam-
matory process.
The aim of this thesis was to investigate airway inflammation bio-
markers in asthma and rhinitis in the context of rhinitis and asthma as 
one disease. We assessed markers of inflammation in the upper and lower 
airways of patients with allergic and nonallergic rhinitis and asthma.
A total of 336 men and women aged between 31 and 49 years 
from separate study populations were examined. Study population A 
was divided into four groups on the basis of their medical history and 
clinical examination: allergic rhinitis, allergic rhinitis with concomitant 
asthma, nonallergic rhinitis and healthy controls. Similarly, population 
B was divided into three groups: persistent and non-persistent long term 
asthma, and healthy controls. We assessed inflammatory cells, cytokines 
and microRNA levels in the nasal biopsies, and exhaled and nasal nitric 
oxide levels in both populations. In addition, in Population A, nasal 
computed tomography (CT) scans as well as sputum and nasal lavage 
fluid proteomics were analysed.
We found only modest differences between the nasal inflammatory 
cells and cytokine levels in the nasal biopsies of the patients with al-
lergic rhinitis and asthma and the controls. In population A, we found 
up-regulations of microRNAs miR-155, miR-205 and miR-498 in 
the nasal biopsies of the subjects with current allergic rhinitis, and a 
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down-regulation of let-7e in asthmatic patients without current rhinitis 
symptoms compared to healthy controls. In population B, miR-498, 
miR-187, miR-874, miR-143 and miR-886-3 were up-regulated in the 
nasal biopsies of the patients with long-term asthma, and miR-18a, miR-
126, let 7e, miR-155 and miR-224 were down-regulated. Four of these 
microRNAs were also down-regulated in the asthmatic patients without 
allergic rhinitis. We only detected trends of differences between the mi-
croRNA expression of the non-persistent and persistent asthma groups. 
Compared to the controls, the level of nasal nitric oxide was slightly 
elevated in the subjects with allergic rhinitis in the study population A, 
but not in those with nonallergic rhinitis. A positive correlation between 
the nasal and exhaled nitric oxide levels (r=0.38, p<0.01) and an inverse 
correlation between the nasal nitric oxide level and sinus ostia obstruction 
(r=-0.27, p=0.013) was detected. When we evaluated the allergic rhinitis 
patients without marked sinus ostial obstruction, the nasal nitric oxide 
level correlated positively with the sinus opacification score (r=0.25, 
p=0.033) as well as with the nasal eosinophil count (r=0.29, p=0.030).
In the subgroup of Population A, we identified 31 different proteins 
in the sputum proteome analysis, most of which were also found in 
nasal lavage fluid. An increased abundance of fatty acid binding protein 
5 (FABP5) was found in the sputum of the asthmatics. In the immuno-
logical validation of Population A, we found increased levels of FABP5 
protein both in the sputum and in the nasal lavage fluid of the asthmat-
ics. Positive correlations between the FABP5 and vascular endothelial 
growth factor (VEGF) levels (r=0.66, p<0.01), as well as between the 
FABP and cysteinyl leukotriene levels (r=0.54, p<0.01) were detected in 
the nasal lavage fluid, suggesting that FABP5 may contribute to airway 
inflammation and remodeling.
Conclusions: We found differentially expressed microRNAs in nasal 
mucosa in allergic rhinitis and asthma. Among the asthmatics, differences 
in the microRNAs were also detected when no significant changes in the 
inflammatory cells and cytokines were found. In the future, microRNAs 
arrays might be useful as a sensitive method for assessing airway inflam-
mation. The nasal nitric oxide level reflects eosinophilic inflammation 
in nasal mucosa in allergic rhinitis. However, the level is dependent on 
sinus ostia obstruction, reducing its feasibility in monitoring allergic 
inflammation. The marker of asthmatic inflammation that we found 
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in sputum, was also detected in the nasal lavage fluid of the asthmatics. 
Samples from upper airways are easy to obtain, and our findings suggest 
that they might be useful in investigating lower airway inflammation 
in asthma. 
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tiiviStelmä
Kroonista nuhaa ja astmaa esiintyy yleisesti aikuisikäisissä väestöissä 
ympäri maailman. Suurimmalla osalla astmaatikoista on myös krooninen 
nuha ja monilla nuhapotilailla todetaan astma. Astmaan ja allergiseen 
nuhaan liittyvässä hengitystietulehduksessa todetaan samankaltaisia 
piirteitä. Näin ollen astma ja nuha voidaan nähdä saman sairauden eri 
ilmentyminä, joihin liittyy samanlainen hengitysteiden tulehdusprosessi.
Tavoitteenamme oli tutkia astmaan ja nuhaan liittyvää hengitystie-
tulehdusta perustuen ajatukseen, että astma ja nuha kuuluvat samaan 
tautikokonaisuuteen. Tutkimme ylä- ja alahengitysteiden tulehdusmerk-
kiaineita allergista ja ei-allergista nuhaa ja astmaa sairastavilla henkilöillä.
Yhteensä 336 iältään 31–49-vuotiasta henkilöä osallistui tutkimuksiin 
muodostaen kaksi tutkimusaineistoa. Tutkimusaineistoon A kuuluvat 
henkilöt jaettiin neljään ryhmään sairaushistorian ja kliinisten tutkimus-
ten perusteella. Ryhmät olivat allergista nuhaa, allergista nuhaa ja astmaa, 
ei-allergista nuhaa sairastavat sekä terveet verrokit. Tutkimusaineistoon 
B kuuluvat pitkään astmaa sairastaneet ja terveet henkilöt jaettiin kol-
meen ryhmään: oireettomat tai ajoittaisesti oireilevaa astmaa sairastavat, 
jatkuvasti oireilevaa astmaa sairastavat ja terveet verrokit. Analysoimme 
tulehdussoluja, sytokiini- ja microRNA-tasoja nenäbiopsianäytteistä 
sekä uloshengitysilman ja nenän typpioksidipitoisuutta molemmissa 
tutkimusaineistossa. Aineistossa A tutkimme lisäksi nenän tietoko-
nekuvia sekä indusoituja ysköksiä ja nenähuuhtelunäytteitä käyttäen 
proteomiikkamenetelmää. 
Nenän limakalvonäytteiden tulehdussoluissa ja sytokiinitasoissa to-
dettiin vain vähäisiä muutoksia astmaa ja nuhaa sairastavilla terveisiin 
verrokkeihin verrattuna. Tutkimusaineistossa A tutkittavilla, joilla oli 
tutkimushetkellä allergisen nuhan oireita, todettiin micro-RNA-tasojen 
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miR-155, miR-205 ja miR-498 olevan koholla. Astmaa ja allergista nu-
haa sairastavilla henkilöillä, joilla ei ollut tutkimushetkellä nuhaoireita, 
todettiin let-7e-tason madaltuminen. Tutkimusaineistossa B pitkään ast-
maa sairastaneilla henkilöillä todettiin miR-498-, miR-187-, miR-874-, 
miR-143- ja miR-886-3-tasojen lisääntyneen ja miR-18a-, miR-126-, 
let 7e-, miR-155- ja miR-224-tasojen vähentyneen nenän limakalvolla. 
Näistä neljän microRNA:n ilmentymisen todettiin vähentyneen myös 
niillä astmaatikoilla, joilla ei todettu allergista nuhaa. MicroRNA tasois-
sa todettiin vain viitteellisiä eroja oireettomia tai ajoittaisesti oireilevaa 
astmaa sairastavia ja jatkuvasti oireilevaa astmaa sairastavia verrattaessa.
Aineistossa A nenän typpioksidipitoisuus oli lievästi koholla aller-
gista nuhaa sairastavilla, sen sijaan ei-allergista nuhaa sairastavien taso 
ei poikennut kontrolliryhmästä. Nenän ja uloshengitysilman typpi-
oksidipitoisuuden välillä todettiin positiivinen korrelaatio (r = 0.38, 
p < 0.01). Lisäksi nenän typpioksidin ja sivuonteloiden aukkojen eli 
ostiumien ahtauman välillä todettiin negatiivinen korrelaatio (r = -0.27, 
p = 0.013). Kun tutkimme allergista nuhaa sairastavia henkilöitä, joiden 
sivuonteloiden ostiumit eivät olleet merkittävästi ahtautuneet, totesimme 
nenän typpioksidipitoisuuden korreloivan positiivisesti sivuonteloiden 
radiologisen samentuman tason (r = 0.25, p = 0.033) kanssa sekä nenä-
biopsian eosinofiilien määrän kanssa (r = 0.29, p = 0.030).
Tunnistimme 31 eri proteiinia ysköksen proteomianalyysissä, joka 
suoritettiin osalle aineiston A näytteistä. Suurin osa proteiineista tun-
nistettiin myös nenähuuhtelunesteestä. Fatty acid binding protein 5 
(FABP5) -pitoisuus oli lisääntynyt astmaatikkojen ysköksissä. Immuno-
logisessa validoinnissa aineistossa A totesimme FABP5-tason olevan 
koholla astmaa sairastavilla sekä ysköksessä että nenähuuhtelunesteessä. 
FABP5-taso korreloi positiivisesti vascular endothelial growth factor 
(VEGF) -tason (r = 0.66, p < 0.01) ja kysteinyyli leukotrieenitason 
(r = 0.54, p < 0.01) kanssa nenähuuhtelunesteessä viitaten FABP5-
proteiinin osallistuvan tulehdukseen ja tyvikalvon paksuuntumiseen 
johtavaan prosessiin.
Johtopäätökset: Totesimme microRNA-tasoissa muutoksia nenän 
limakalvolla allergista nuhaa ja astmaa sairastavilla henkilöillä. Muu-
toksia todettiin astmaatikoilla myös silloin, kun merkittäviä muutoksia 
tulehdussoluissa tai sytokiineisssa ei todettu. Tulevaisuudessa micro-
RNA-analyysistä voi kehittyä herkkä menetelmä hengitystietulehduksen 
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arviointiin. Nenän typpioksidipitoisuus kuvastaa eosinofiilista tulehdusta 
nenän limakalvolla. Nenän sivuonteloiden ostiumien ahtauma kuitenkin 
vaikuttaa typpioksiditasoon vähentäen mittauksen käyttökelpoisuutta al-
lergisen tulehduksen seurannassa. Löysimme astmaattiseen tulehdukseen 
liittyvän merkkiaineen ysköksestä, ja sen taso oli koholla myös nenähuuh-
telunesteessä astmaa sairastavilla. Ylähengitysteistä on alahengitysteitä 
helpompi ottaa näytteitä, ja jatkossa ylähengitysteistä otettavat näytteet 
voivatkin olla hyödyllisiä myös astmaattisen tulehduksen mittaamisessa.
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1 intRoDuction
Asthma and chronic rhinitis are both common chronic diseases all over 
the world (Zacharasiewicz et al. 2003; Bahadori et al. 2009). The preva-
lence of asthma and allergic rhinitis has increased rapidly in the latter 
half of the last century, however in some developed countries with a high 
prevalence, a levelling off in this prevalence has been detected in recent 
years (Eder et al. 2006; Bousquet et al. 2008b). In Finland, no signs of 
plateauing have been detected. In the recent report, the prevalence of 
phycisian-diagnosed asthma was 10.0% and the prevalence of allergic 
rhinoconjunctivitis was 44.4% in the adult Finnish population (Kainu 
et al. 2013). It has been indicated that asthma and rhinitis often coex-
ist. In a Swedish study, 63.9% of asthmatics had concomitant allergic 
rhinitis and 39.8% had chronic rhinitis, and 19.8% of subjects with 
allergic rhinitis also had asthma (Eriksson et al. 2011). 
Upper and lower airways form a single entity. Dividing respiratory 
diseases into two categories based on medical specialities (ear, nose and 
throat or lung diseases) sometimes seems to blur this fact. The main 
physiological function of the nose is to condition the inhaled air before 
it reaches the lower airways. Nasal cavities have a good capacity to hu-
midify and filter the air, and nasal mucus and mucociliary clearance are 
essential in the filtering of inhaled particles and gaseous materials. In 
addition, nitric oxide produced in upper airways has a protective role in 
the entire respiratory track, as it has antiviral, bacteriostatic and bron-
chodilatory effects and it improves oxygenation (Lundberg et al. 1999). 
Nasal epithelium has also an important role in immunity, it is constantly 
engaged in immunomodulation between the host and the environment. 
The nasal and bronchial mucosa have histological similarities and allergic 
inflammation in the nasal mucosa and in the bronchus displays several 
common characteristics including Immunoglobulin E (IgE) dependent 
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mast cell activation, eosinophilic infiltration and an increase of T helper 2 
(Th2) type lymphocytes and cytokines. Moreover, not only has a similar 
inflammation in the upper and lower airways has been found, but nasal 
inflammation has been shown to have effects on the lower airways and 
vice versa (Togias 2003; Braunstahl et al. 2006). Allergic asthma and 
rhinitis can be seen as manifestations of one disease, in the concept of 
“one airway one disease” or “united airway disease”. 
In recent years the methods to analyse biological samples have devel-
oped rapidly, providing good opportunity to investigate mechanisms of 
allergic inflammation and to identify new biomarkers. The objective of 
the present series of studies was to assess airway inflammation in rhinitis 
and asthma, and to identify potential biomarkers in asthma and rhinitis 
in the upper and lower airways in the “one airway one disease” context. 
We evaluated microRNA (miRNA) expressions in the nasal mucosa as 
well as the nasal nitric oxide levels of subjects with rhinitis and asthma. 
Furthermore, we conducted proteomic analysis of the induced sputum 
to reveal differences in the protein abundances.
19
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2.1  Asthma
2.1.1  Definition and diagnosis of asthma
The pathogenesis of asthma is not completely understood, so much of 
its definition is descriptive. The current Global Initiative for Asthma 
(GINA) (2014) guideline defines asthma as “a heterogeneous disease, 
usually characterized by chronic airway inflammation. It is defined by the 
history of respiratory symptoms such as wheezing, shortness of breath, 
chest tightness and coughing that vary over time and in intensity, together 
with variable expiratory airflow limitation”. 
Although airway inflammation has been found to be essential in the 
pathogenesis of asthma, based on the current international and Finnish 
guidelines the diagnosis is based on typical symptoms of asthma and 
changes in pulmonary function. In the current GINA guidelines, the 
diagnostic criteria are documented airflow limitation, at least once dur-
ing the diagnostic process forced expiratory flow in one second (FEV1)/
Forced vital capacity (FVC), and documented excessive variation in lung 
function including one of the following: 1) the increase of FEV1 ≥12% 
and 200ml in response to bronchodilator in spirometry, 2) average di-
urnal daily variation of peak expiratory flow (PEF) >10% in twice-daily 
PEF over two weeks, 3) the increase of FEV1 ≥12% and 200ml (or PEF by 
>20%) from baseline after four weeks of anti-inflammatory treatment, 4) 
fall in FEV1 >10% and 200ml from baseline in the exercise test, 5) posi-
tive bronchial challenge test, or 6) variation of FEV1 ≥12% and 200ml 
between visits outside respiratory infections (GINA 2014). The Finnish 
criteria include one of the following findings 1) the increase of FEV1 or 
FVC ≥12% and 200ml in response to bronchodilator in spirometry, 2) 
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the ≥15% increase of PEF and 60 l/min in response to bronchodilator 
or diurnal variation of ≥20% and 60 l/min in PEF at least three times 
during two weeks of monitoring, 3) an increase in FEV1 of ≥15% or 
an average PEF if at least 20% after anti-inflammatory treatment, 4) 
moderate or severe hyperresponsiveness in the histamine or methacoline 
test or 5) a ≥15% fall in FEV1 in the exercise test (Asthma: Current Care 
Guidelines Abstract, 2012).
2.1.2 Phenotypes of asthma
Almost 70 years ago, Rackeman (1947) introduced the concept of 
extrinsic (allergic) and intrinsic (nonallergic) subtypes of asthma based 
on the clinical manifestation of the disease. Extrinsic asthma had an 
early onset, was associated to atopy (IgE detected to specific allergens), 
allergic triggers could be identified, and other allergic diseases or family 
history of allergic diseases were also detected. Intrinsic asthma had onset 
in adulthood, was not related to allergic sensitisation, and exacerbation 
related to aspirin intake could be detected in some cases.
In recent years, asthma heterogeneity has been better understood and 
several studies utilizing cluster analyses have increased the knowledge of 
phenotypes i.e. combinations of clinical characteristics and their link to 
biology (Weatherall et al. 2009; Siroux et al. 2011; Anto et al. 2012). 
However, more information is still needed to form a full picture of true 
asthma phenotypes. In addition, many environmental factors such as 
smoking, infection and occupational exposures can influence the un-
derlying inflammatory processes. 
Haldar and colleagues (2008) divided asthma patients into five clinical 
phenotypes: 1) Early symptom predominant, having early onset, normal 
body mass index (BMI) and high symptom expression, 2) obese non-
eosinophilic with late onset, female preponderance and high symptom 
expression, 3) mixed middle-aged cohort with well-controlled symptoms, 
inflammation and benign prognosis, 4) early onset atopic asthma having 
concordant symptoms, inflammation and airway dysfunction, and 5) 
inflammation predominant with late onset, mostly men, few daily symp-
toms, but active eosinophilic inflammation. 
More recently, Wenzel and colleagues (2012) categorised adult asthma 
into five phenotypes. 1) Early-onset asthma phenotype usually originat-
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ing in early childhood, with an atopic and allergic component and the 
severity of asthma varying from mild to severe. It typically coexists with 
other atopic diseases, allergic rhinitis and atopic dermatitis, and the 
level of total and allergen-specific IgE is often high. Th2-type immune 
process is usually associated with this phenotype. 2) In late-onset eosino-
philic asthma, elevated numbers of eosinophils can be found in sputum, 
in bronchoscopic samples or in blood. However, allergy is seldom de-
tected. The onset of asthma is in adulthood, it is often severe from the 
beginning, and associated with sinusitis, nasal polyps and is sometimes 
aspirin-exacerbated. Th2-type inflammation is also associated with this 
phenotype. 3) Subjects with exercise-induced asthma usually have mild 
asthma and experience bronchoconstriction in response to exercise. It is 
associated with mast cells and their mediators and Th2-type immunity. 
4) Obesity-related asthma originates in adulthood mostly in women; these 
asthmatics are often very symptomatic, but airway hyperresponsiveness 
is seldom detected. This phenotype is not associated with Th2-type 
inflammation. 5) In the neutophilic asthma phenotype, neutrophilia is 
detected in sputum. This asthma phenotype is associated with clinical 
features of low FEV1 and air trapping. Th2-type inflammation is not 
detected. Instead, neutrophilia is linked with Th17 inflammation. It is 
estimated that 50% of people with asthma belong to the Th2-associated 
phenotypes. 
Moreover, the term endotype has been used to distinguish subtypes of 
asthma. Endotype is defined as the subtype of a condition that is defined 
by distinct functional or pathophysiological mechanism (Anderson 2008; 
Lötvall et al. 2011). Phenotypic characteristics represent observations of 
the clinical dimensions of asthma, whereas an asthma endotype represents 
a mechanistically coherent disease entity. Each endotype may include 
several phenotypes, or some phenotypes may be present in more than 
one endotype. Lötvall and colleagues (2011) chose seven parameters 
to differentiate categories including clinical characteristics, biomarkers 
(eosionophilia, exhaled nitric oxide, skin prick tests (SPT), IgE, lung 
physiology, genetics, histopathology, epidemiology) and treatment re-
sponse. They present six endotypes. 1) Aspirin-sensitive asthma, where 
the disease mechanism is likely eicosanoid related. 2) Allergic bronchopul-
monary mycosis being a hypersensitive reaction to the colonisation of the 
airways (usually Aspergillus fumigatus). 3) Adult allergic asthma and 
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4) Children with asthma-predictive indices are driven by a Th2 driven in-
flammatory process. 5) The severe late-onset hypereosinophilic asthma group 
includes about 20% of asthma patients; these patients are non-atopic 
and the disease mechanisms are still mainly unknown. 6) Cross-country 
skiers’ asthma is clinically defined as asthma symptoms associated with 
strenuous skiing-related exercise. It is seldom associated with allergic 
sensitisation and airway inflammation is dominated by increased numbers 
of lymphocytes, macrophages and neutrophils.
2.1.3  Asthma control and severity
According to the current GINA guidelines (2014), the asthma control 
level is the extent to which the manifestations of asthma can be observed 
in the patients, or have been reduced or removed by treatment. It is de-
termined by the interaction between the patient’s genetic background, 
underlying disease processes, the treatment they are receiving, the envi-
ronment, and psychosocial factors. 
The assessment of asthma control suggested by the GINA guidelines 
has not been formally validated (GINA 2014). It includes both the as-
sessment of current clinical manifestations (symptoms, night waking, 
reliever medication use, and activity limitation) and control of the ex-
pected future risk to the patient such as exacerbations, accelerated decline 
in lung function, and side-effects of treatment. The assessment should 
preferably cover a period of four weeks. The level of asthma control is 
classified as well controlled, partly controlled and uncontrolled. Asthma 
is controlled if a patient does not have daytime asthma symptoms or 
the need for reliever medication more than twice a week, no limitation 
of activities, no nocturnal symptoms or awakenings. A low FEV1 is 
an independent predictor of asthma exacerbations and lung function 
decline. Asthma outcomes have shown to improve after the introduc-
tion of control-based guidelines, and currently, control-based asthma 
management is recommended by GINA (2014) and the Finnish Asthma 
Current Care Guidelines (2012). 
According to the current GINA guidelines asthma severity is evaluated 
retrospectively from the level of treatment required to control exacerba-
tions and symptoms (GINA 2014). It is possible to assess the severity 
of asthma when the patient has been on regular controller treatment for 
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several months. Mild asthma can be well controlled with low-intensity 
asthma treatment, for example low-dose inhaled steroids or leukotriene 
(LT) antagonists. Moderate asthma is well controlled with a low-dose 
inhaled corticosteroid /long-acting bronchodilator medication, for ex-
ample. Severe asthma requires high-intensity treatment to maintain good 
control or good control is not achieved despite such medication. Asthma 
severity is not a permanent feature in an individual, it may change over 
the months and years.
2.2  Rhinitis
2.2.1 Definition of rhinitis
According to the global guidelines on Allergic Rhinitis and its Impact 
on Asthma (ARIA) rhinitis is defined as “an inflammation of the lining 
of the nose and it is characterized by nasal symptoms including anterior 
or posterior rhinorrhoea, sneezing, nasal blockage and/or itching of the 
nose. These symptoms occur during two or more consecutive days for 
more than one hour on most days” (Bousquet et al. 2001; Bousquet et 
al. 2008b). 
2.2.2 Definition and diagnosis of allergic rhinitis
Allergic rhinitis is clinically defined as a symptomatic disorder of the 
nose induced after allergen exposure by an IgE-mediated inflammation 
(Bousquet et al. 2008b). Symptoms of allergic rhinitis include rhinor-
rhoea, nasal obstruction, nasal itching and sneezing which are reversible 
spontaneously or with treatment. Postnasal drip mainly occurs with 
profuse anterior rhinorrhoea. Allergic rhinitis is often associated with 
ocular symptoms. The diagnosis is based on the concordance between 
typical allergic symptoms and diagnostic tests including allergen specific 
IgE and SPT.
2.2.3 classification of allergic rhinitis
Earlier, allergic rhinitis was classified as seasonal, perennial and occu-
pational based on the time of the exposure and symptoms (Dykewicz 
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et al. 1998). The ARIA document in 2001, introduced a classification 
including intermittent and persistent allergic rhinitis (Bousquet et al. 
2001). Intermittent means that the symptoms are present less than four 
days a week or for less than four weeks, whereas in persistent allergic 
rhinitis the symptoms are present for more than four days a week and for 
more than four weeks. Information on the phenotypes of allergic rhinitis 
based of unbiased analyses combining clinical features and underlying 
processes is currently lacking (Anto et al. 2012). 
2.2.4  Definition and diagnosis of nonallergic rhinitis
Several nonallergic conditions can cause rhinitis symptoms including 
infections, hormonal imbalance, physical agents, anatomical anomali-
ties and medications (Bousquet et al. 2008b). In most cases the cause 
of rhinitis cannot be detected and it is called nonallergic rhinitis or 
“idiopathic rhinitis”, also referred as “nonallergic noninfectious rhini-
tis” or “vasomotor rhinitis” (Settipane et al. 2013). The terminology is 
somewhat unestablished. Nonallergic rhinitis is diagnosed when a patient 
has symptoms that mimic allergic rhinitis, with no definite causal fac-
tor and with a lack of demonstrated IgE mediated allergy by SPTs and 
allergen specific IgE (Bousquet et al. 2008a). It is largely an exclusion 
diagnosis and thus a heterogeneous condition. Primary symptoms are 
nasal congestion and rhinorrhoea. However, nasal pruritus, sneezing 
and conjunctival symptoms are rare (Settipane et al. 2013). Patterns of 
symptoms may be perennial, persistent or intermittent. Precipitants for 
nonallergic rhinitis can be changes in climate (temperature, humidity 
and barometric pressure), strong odours, environmental tobacco smoke, 
pollutants, chemicals and other occupational exposures, exercise or 
alcohol ingestion. 
Nonallergic rhinitis with eosinophilia syndrome was first described 
in 1981 (Jacobs et al. 1981). These patients, usually middle aged adults, 
have perennial nasal symptoms including sneezing, rhinorrhoea, nasal 
pruritus and reduced sense of smell. Marked eosinophilia is detected in 
nasal cytology, but no IgE mediated immunologic reaction to common 
inhalation allergens is seen. This syndrome may be responsible of approxi-
mately 30% of all rhinitis cases without allergy (Settipane et al. 1985).
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In recent years, a condition called local allergic rhinitis or Entopy 
has been described. That is a local nasal IgE production and reactivity 
to allergens without detectable systemic atopy i.e. negative SPTs and 
specific serum IgE to aeroallergens (Powe et al. 2003).
Other types of nonallergic, noninfectious chronic rhinitis that are not 
caused by anatomical or mechanical causes or other medical conditions 
are gustatory rhinitis occurring after indigestion of foods and drinks, 
atrophic rhinitis, medication associated rhinitis, hormone induced rhi-
nitis and rhinitis of elderly subjects (Settipane et al. 2013).
2.2.5  Severity of rhinitis
Allergic rhinitis symptom severity is classified as mild when no sleep 
disturbance or bothersome symptoms are present and daily activities and 
school or work performance is not affected. In the moderate/severe form 
one or more of the above mentioned items are present (Bousquet et al. 
2001). Visual analogue scale (VAS) is an objective, quantitative measure 
of rhinitis symptom severity (Spector et al. 2003). Separate symptoms 
such as sneezing, runny nose, nasal congestion and itching or global 
rhinitis symptoms may be assessed by using a VAS scale. On the VAS 
scale of 1‒10 cm, patients with a VAS of global rhinitis symptoms of <5 
cm can be classified as mild in ARIA classification and a VAS of > 6cm 
is equivalent to moderate/severe AR (Bousquet et al. 2007). 
2.3  Prevalence and co-existence of asthma  
 and rhinitis in adults
2.3.1  Prevalence of asthma
There is no single question to define asthma in the questionnaires in 
epidemiologic studies. Questions about physician-diagnosed asthma and 
asthma symptoms have been used. The prevalence rates of asthma using 
both of these definitions are dependent on the awareness of asthma in the 
population (Eder et al. 2006). It has been estimated, that approximately 
300 million people currently have asthma and that it affects 1‒18% 
of the population in different countries (Bahadori et al. 2009; GINA 
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2014). The World Health Survey included almost 180 000 adults from 
70 countries. The prevalence of physician-diagnosed asthma was 4.3%, 
clinical/ treated asthma was 4.5% and wheezing 8.6% (To et al. 2012). 
However, the prevalence varied 21-fold in different countries. The 
highest prevalence was reported in Australia, where the prevalence of 
physician-diagnosed asthma was 21.0%, clinical/treated asthma 21.0%, 
and wheezing 27.4%. A high prevalence was seen also in North and West 
European countries and in Brazil.
The prevalence of asthma has increased worldwide in the second half 
of the last century (Eder et al. 2006). Some studies have reported that 
it plateaued thereafter, especially in countries with high asthma rates 
(Anderson et al. 2007; Lotvall et al. 2009) while other studies suggest 
that it is still increasing (Gershon et al. 2010). The systematic review of 
the epidemiological studies concluded that there is no overall signs of 
a declining trend of asthma prevalence; on the contrary, an increasing 
trend was suggested in many parts of the world (Anandan et al. 2010). 
In Finland the prevalence of asthma has increased during recent 
decades, signs of levelling off have not been reported. In 1980, the preva-
lence of asthma was 4.1% in the urban population and 2.7% in the rural 
population (Heinonen et al. 1987). These figures were based on postal 
questionnaire answers and a random subset of responders were clinically 
examined. In 1996, the prevalence of physician-diagnosed asthma among 
first year university students was 4.2% (Kilpeläinen et al. 2000) and 
in Päijät-Häme region in southern Finland the non-response adjusted 
prevalence of physician-diagnosed asthma in the adult population was 
4.4% (Hedman et al. 1999). An increase in the asthma prevalence of 
Finnish men recruited to the army was 20-fold between 1961 and 1989 
(Haahtela et al. 1990). After this, no plateauing has been detected, and 
a 3.5% prevalence was detected in 2003 (Latvala et al. 2005). In the, 
the prevalence of physician-diagnosed asthma in the adult population 
was 6.0% in Lapland (Kotaniemi et al. 2002) and 6.8% in the Helsinki 
area in 1996 (Pallasaho et al. 1999. A recent study of the FinEsS popu-
lation by Kainu and colleagues (2013) reported that the prevalence of 
physician-diagnosed asthma had increased in the adult population in 
the Helsinki area from 6.5% in 1996 to 10.0% in 2006. However, the 
change in the prevalence of respiratory symptoms suggestive of obstruc-
tive airway diseases was less distinct.
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2.3.2 Prevalence of rhinitis
The definition of rhinitis has been difficult in epidemiological studies, in 
which the characterization of rhinitis symptoms is often not a primary 
objective. A large proportion of subjects defined as having allergic rhi-
nitis in epidemiological studies do not have positive SPT or specific IgE 
in serum. In the study by Vervloet and colleagues (1991) only 42% of 
subjects reporting a history of hay fever had an elevation of specific IgE. 
In addition, many studies of allergic rhinitis focus on questions about 
hay fever leaving perennial symptoms underestimated. Moreover, sinus 
imaging is seldom performed, and thus rhinosinusitis cannot be excluded.
It has been estimated that the prevalence of rhinitis including aller-
gic and nonallergic forms in the adolescent/adult population is at least 
25% (Leynaert et al. 1999; Zacharasiewicz et al. 2003; Bachert et al. 
2006; Molgaard et al. 2007; Bousquet et al. 2008a). Zacharasiewicz and 
colleagues assessed 22 population-based studies on rhinitis and found 
that the proportion of rhinitis cases that were attributable to atopy was 
approximately 50%, suggesting that other half was due to nonallergic 
mechanisms (Zacharasiewicz et al. 2003). The idiopathic form comprises 
approximately 71% of nonallergic rhinitis conditions (Settipane 2009). 
Nonallergic rhinitis is twice as common in women as in men, whereas 
in allergic rhinitis the gender distribution is more equal (Molgaard et 
al. 2007). Both allergic rhinitis and nonallergic rhinitis symptoms may 
exist in the same subject. It has been suggested that this rhinitis subtype 
may represent 44 to 87% of allergic rhinitis patients and is more com-
mon than the pure allergic or nonallergic type of rhinitis (Bernstein 
2010). In a Belgian population study on subjects aged over 15 years, the 
prevalence of allergic rhinitis was 29.8% and that of nonallergic rhinitis 
9.6%. Altogether 40.8% of allergic rhinitis patients and 23.5% of nonal-
lergic rhinitis patients had persistent symptoms. Symptom intensity was 
moderate or severe in 75.4% of allergic rhinitis patients and 53.1% of 
nonallergic rhinitis patients (Bachert et al. 2006).
The increase in the prevalence of allergic rhinitis has been observed 
since 1960s (Bousquet et al. 2008b). There is evidence that the increase 
in the prevalence of allergic rhinitis has levelled off in countries in which 
the prevalence of allergy and rhinitis is high (Braun-Fahrlander et al. 
2004; Eriksson et al. 2012), but in countries where the prevalence is low 
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a continuing increase is seen. Trends of asthma and rhinitis prevalence are 
similar, but are not always in line with each other (Bousquet et al. 2008b).
The prevalence of allergic rhinitis has increased in Finland during the 
last decades among adults; a levelling off in the prevalence has not been 
detected. In the follow-up study in the population of young and middle-
aged twins, the prevalence of physician-diagnosed hay fever was 6.8% 
in men and 11.8% in women in 1975 and in 1990 it was 9.8% in men 
and 15.8% in women (Huovinen et al. 1999). In 1980, the prevalence 
of allergic rhinitis was 26.7% in the urban population and 28.8% the 
rural population (Heinonen et al. 1987). In the young adult student 
population studied in 1996, the prevalence of doctor-diagnosed allergic 
rhinitis was 21.5% (Kilpeläinen et al. 2000). In the adult population in 
Päijät-Häme region, the prevalence of allergic rhinitis was 37.7% in 1996 
(Hedman et al. 1999). In the study of cohort originating from Tampere 
area, the prevalence of allergic rhinitis was 17.5% at the age of 16 in 1983 
and 26% at the age of 32 in 1999 (Huurre et al. 2004). In the cohort 
of young adults in northern Finland, the prevalence of allergic rhinitis 
symptoms in past year was 30% in non-farmers and 23% in professional 
farmers at the age of 31 in 1997 (Lampi et al. 2011). Latvala and col-
leagues (2005) showed that the prevalence of allergic rhinitis in young 
men at call up for military service has increased rapidly since 1991, being 
8.9% in 2000. In the recent study of Kainu and colleagues (2013) the 
prevalence of allergic rhinoconjunctivitis increased from 37.2% in 1996 
to 44.4% in 2006 in the adult population of Helsinki. 
2.3.3 co-existence of asthma and rhinitis
The co-existence of asthma and rhinitis is common. In the European 
multi-centre study, European Community Respiratory Health Survey 
(ECRHS), perennial rhinitis was strongly associated with asthma in at-
opic subjects (odds ratio 8.1) and also in nonatopic subjects (odds ratio 
11.6) (Leynaert et al. 1999). In a recent Swedish study, 63.9% of asth-
matic subjects had concomitant allergic rhinitis and 39.8% had chronic 
rhinitis and the prevalence of asthma in subjects with allergic rhinitis was 
19.8% (Eriksson et al. 2011). In outpatient population, concomitant 
allergic rhinitis was present in 73.9% and nonallergic rhinitis in 13.6% 
of asthma patients (Vandenplas et al. 2010). 
29
2 literature review
Rhinitis is a risk factor for asthma development. In the 8.8-year 
follow-up study of ECRHS cohort, the relative risk for development of 
asthma was 2.71 for nonallergic rhinitis and 3.53 for allergic rhinitis as 
compared with subjects without rhinitis (Shaaban et al. 2008). In the 
nested case-control study from Sweden, asthma was also associated with 
the occurrence of non-infectious rhinitis before asthma onset (odds ratio 
5.4) (Toren et al. 2002). In the Finnish 11-year follow-up study the 
subjects with allergic rhinoconjuctivitis had 2.15 fold risk of developing 
asthma (Pallasaho et al. 2011). Karjalainen and colleagues (2003) found 
4.8 fold risk of asthma in the subjects with occupational rhinitis. 
Rhinitis may also have an influence on the asthma control and sever-
ity. Magnan and colleagues reported that the severity of allergic rhinitis 
was associated with the severity of asthma and that allergic rhinitis was 
associated with worse asthma control (Magnan et al. 2008). Consistent 
with this, Vandenplas and colleagues (Vandenplas et al. 2010) reported 
that both allergic and nonallergic rhinitis were associated with the in-
creased risk of uncontrolled asthma. Also, in the study of Eriksson and 
colleagues (2011) subjects with concomitant allergic rhinitis had more 
asthma symptoms. In a one year follow-up study moderate/severe rhinitis 
predicted greater asthma severity and worse asthma control in severe 
asthma patients (Ponte et al. 2008). On the contrary, in the ECRHS 
cohort allergic rhinitis was not associated with asthma severity (de Marco 
et al. 2006). Also, no clear association was detected between asthma and 
rhinitis severity in mite allergic patients (Antonicelli et al. 2013). 
2.4  Allergic airway inflammation 
2.4.1  Definition of allergy, allergen and atopy
In 2004 The World Allergy Organization defined allergy as “a hyper-
sensitivity reaction initiated by immunological mechanisms. Allergy 
can be antibody- or cell-mediated. In the majority of cases the antibody 
responsible for an allergic reaction belongs to the IgE isotype and these 
individuals may be referred to as suffering from an IgE-mediated allergy”. 
Allergens are defined as antigens that cause allergy and atopy is a “personal 
and/or familial tendency, usually in childhood or adolescence, to become 
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sensitized and produce IgE antibodies in response to ordinary exposure 
to allergens, usually proteins. As a consequence, such individuals can 
develop typical symptoms of asthma, rhinoconjunctivitis, or eczema” 
(Johansson et al. 2004).
2.4.2  Allergic inflammation process
The allergic inflammatory process in the upper and lower airways in 
allergic rhinitis and asthma is mainly similar (Bousquet et al. 2008b). 
The nasal and bronchial mucosa have both pseudostratified epithelium 
and ciliated and columnar cells resting on the basement membrane. The 
biggest differences in the histology are in the submucosal level. In the 
nose a large and highly developed vasculature is seen, whereas bronchial 
airways are surrounded by smooth muscle bundles. The clinical differ-
ences are predominantly due to anatomical differences and the interaction 
between inflammation and structural cells; vasodilatation in the upper 
airways leads to nasal blockage and airway smooth muscle cells in the 
bronchus result in bronchoconstriction.
Allergen exposure in sensitized individuals induces an early phase of 
allergic inflammation. It involves an acute activation of allergy effector 
cells (mast cells and basophils) through IgE-allergen interaction and mast 
cell and basophil degranulation and the release of histamine, tryptase and 
other mediators including cysteinyl leukotrienes (cysLT) and prostaglan-
dins (PG) (Barnes 2011). The clinical symptoms start within minutes. 
In the nose histamine and other mediators cause sneezing, pruritus, 
nasal congestion and mucus secretion. In asthma, vasodilatation, bron-
choconstriction and plasma exudation takes place leading to wheezing 
and dyspnoea. The late phase typically begins within a few hours in the 
site of allergen challenge. It is characterised by the influx and activation 
of inflammatory cells including T lymphocytes, eosinophils, basophils, 
neutrophils and monocytes. In asthma, chronic inflammation leads to 
airway hyperresponsiveness, globlet cell hyperplasia and airway wall 
remodeling including subepithelial fibrosis, increased smooth muscle 
mass, enlargement of glands, neovascularisation and mucus hyperse-
cretion (Bergeron et al. 2009). Also in nasal mucosa in allergic rhinitis 
remodeling including changes in collagen, proteoglycans and lymphatic 
vessels has been detected (Kim et al. 2010).
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2.4.3 cells related to allergic inflammation
T-lymphocytes develop in the thymus and circulate between secondary 
lymphoid tissue and blood. After the first contact with a specific antigen 
T naïve cells start to proliferate and differentiate into effector T cells. 
Cytotoxic T cells, which express surface marker CD8 and recognize anti-
gens of major histocompatibility complex (MCH) class I, are important 
in the defence against intracellular pathogens, especially viruses. Th cells, 
which express the surface marker CD4 and recognize antigens bound 
to MHC class II molecules, differentiate into various subsets, Th1, Th2 
and Th17, distinguished by the cytokines they produce when activated 
(Akdis et al. 2011). Activated Th1 cells produce interleukin (IL) 2 and 
interferon (IFN) γ; they are important in immunoresponses against 
microbes, in virus defence and also participate in allergic inflammation. 
Th2 cells are essential in the allergic inflammation and also in direct 
immunoresponses against intestinal helminths. Th2 polarisation from 
naïve t cells is initially induced by dendritic cells or exogenous IL-4 from 
basophils or by IL-25 or IL-33. During allergic inflammation Th2 cells 
migrate to the site of inflammation to recruit and activate eosinophils, B 
cells and epithelial cells and switch antibody production to IgE through 
the actions of the cytokines IL-4, IL-5, IL-9 and IL-13 (Robinson et al. 
1992). Th17 cells are a distinct lineage of Th cells expressing IL-17, they 
may mediate neutrophilic type inflammation and they exacerbate Th2 
mediated allergic inflammation (Lloyd et al. 2010; Akdis et al. 2011). 
T regulatory cells control immune homeostasis, prevent autoimmunity, 
supress allergic responses and participate in the resolution of inflamma-
tion. In allergic inflammation T regulatory cells supress inflammation 
through the secretion of inhibitory cytokine IL-10, transforming growth 
factor (TGF) β or by cell surface molecules (Palomares et al. 2010). They 
also have a direct inhibitory effect on dendritic cells and effector T cells 
through cell-to-cell contact. Also other subsets of T cells including Th9 
cells, T follicular helper, Th22 cells have been proposed to participate 
in allergic inflammation (Chang et al. 2010; Lloyd et al. 2010; Akdis 
et al. 2011).
B-lymphocytes mature in the bone marrow and circulate between 
lymph organisms. However, they are also present in the airway mucosa 
(Drolet et al. 2010). B-cells are essential in allergic inflammation through 
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synthesis of IgE. Th2 cells engage cognate B cells through B cell MHC 
class II and co-stimulatory molecules and through secretion of IL-4 and 
IL-13 and induce B cells to undergo a class switch to produce IgE. Also 
other cells may enhance class switch through IL-4 and IL-13 production. 
In addition, B-cells function as antigen presentation cells and secrete 
both inflammatory and regulatory cytokines. 
Dendritic cells form a network that is localised within the epithelium 
and submucosa of the entire respiratory tract including both the nasal 
and bronchial areas (Moller et al. 1996; Hartmann et al. 2006). They are 
the primary antigen-presenting cells in the airways. In allergic inflamma-
tion, dendritic cells engulf allergens, break them into antigenic peptides, 
and migrate to the lymph nodes where they present these peptides to 
naïve T lymphocytes or Th2 cells (Savina et al. 2007). Th2 cell activation 
requires MHC II complexes on the ligation. Dendritic cells can polarise 
naïve T cells into Th1 or Th2 cells according to their own phenotype 
and with signals received from processed antigens and from the tissue 
microenvironment during antigen presentation. 
Mast cells are present in the peripheral tissue, the differentiation and 
maturation of mast cells also takes place there. Along with dendritic 
cells, mast cells are the first immune cells to interact with allergens. In 
the early allergic reaction, allergens activate sensitised mast cells by cross-
linking surface-bound IgE molecules to release preformed mediators 
and lipid-derived mediators including histamine, tryptase, PGD2 and 
LTC4 within minutes (Galli et al. 2012). Other mediators including 
many cytokines, chemokines and growth factors are produced in mast 
cells from new transcripts and are secreted in the hours after mast cell 
activation. Recently, it has been proposed that they also have a role in 
long-term pathophysiological changes and tissue remodelling in asthma 
(Galli et al. 2010).
Eosinophils are the most prominent cells in the late-phase allergic 
airway response (Blanchard et al. 2009). They require IL-5 released by 
Th2-type cells, granulocyte-macrophage colony stimulating factor (GM-
CFS) and eotaxin for their maturation, survival, attraction to the inflam-
mation sites and activation. They release proinflammatory cytokines like 
IL-4, IL-5 and IL-13, TGF-β and cysLTs. Activated eosinophils release 
toxic pre-produced products stored in granules, especially major basic 
protein (MBP), eosinophilic cationic protein (ECP) and eosinophil 
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peroxidase (EPO), and contribute to tissue damage, inflammation and 
airway hyperresponsiveness. 
Basophils form less than 1% of all the granulocytes in the peripheral 
blood. In the allergic reaction basophils release histamine and LTC4 to 
promote inflammation (Siracusa et al. 2013). Basophils have been found 
to play a role in promoting optimal Th2 cytokine responses, and they 
may co-operate with dendritic cells to contribute to pathologic airway 
inflammation.
2.4.4  mediators related to allergic inflammation
Cytokines are small glycosylated proteins that are involved in cellular 
growth, differentiation, proliferation, cell-to-cell signaling, chemotaxis, 
immunomodulation, immunoglobulin isotype switching and apoptosis 
(Hamid et al. 2009; Akdis et al. 2011). The cytokine actions are me-
diated through specific cytokine receptors on the target cell surfaces. 
Depending on the context in which the cytokine is produced or the cell 
type that responds to the cytokine, they may have different functions. 
T cells are the major source of cytokines in allergic inflammation, but 
they also are produced in other inflammatory cells, structural cells and 
in fibroblasts. Allergic airway inflammation is characterised by the se-
cretion of Th2 cytokines, including IL-4, IL-5 and IL-13 (Robinson et 
al. 1992; Veldhoen 2009). In addition to Th2 cells, these cytokines are 
also secreted from mast cells, basophils, eosinophils and structural cells. 
IL-4 and IL-13 are essential in IgE synthesis through isotope switch-
ing of B cells. IL-5 drives eosinophil differentiation, maturation and 
survival. IL-10 is primarily known as an inhibitory cytokine, but it also 
has immunostimulary effects. It is produced from naïve T cells, Th1 and 
Th2 cells and from activated monocytes, mast cells and macrophages. 
IL-10 reduces the effects of pro-inflammatory cytokines and inhibits 
eosinophil survival and migration during allergic inflammation. It can 
also down-regulate IL-4 induced isotype switching of activated B-cells. 
INF-γ is mainly produced in Th1 cells and has inhibitory effect in Th2 
cells. During allergic inflammation it inhibits isotype switching of IgE 
and IgE production of Th cells and it can also promote cell-mediated 
cytotoxic responses. Recent asthma studies suggest that IL-33, IL-25 and 
thymic stromal lymphopoietin (TSLP) predominantly secreted by the 
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airway epithelium promote Th2 cell function and increase IL-5, IL-9 
and IL-13 production (Licona-Limon et al. 2013). Several proinflamma-
tory cytokines, such as IL-1β, IL-6, TNF-α, GM-CSF, and IL-17 have 
also been linked to allergic inflammation (Akdis et al. 2011; Bhakta et 
al. 2011).
Chemokines are small cytokines primarily involved in the chemotaxis. 
Increased levels of chemokines have been detected in bronchial biopsies 
and bronchoalveolar lavage in asthmatic as well as in the nasal mucosa 
of subjects with seasonal allergic rhinitis (Miotto et al. 2001; Plewako et 
al. 2008). They attract and regulate leukocyte trafficking into tissues by 
binding specific receptors. In addition, they have other functions such 
as effecting T cell differentiation. Chemokines are classified into four 
subclasses according to their structure. CC chemokins (or β chemokines) 
including for example IL-8, eotaxin and RANTES are thought to have 
the greatest relevance in asthma (Hamid et al. 1993).
Cysteinyl leukotrienes (CysLT) (LTC4, LTD4 and LTE4) are synthe-
tized from arachidonic acid by inflammatory cells such as mast cells, 
eosinophils, basophils and macrophages. They are released following 
allergen exposure and they predominate both early and late phases of 
the allergic response. They are also involved in the maturation and tis-
sue recruitment of inflammatory cells as well as in airway remodeling 
(Holgate et al. 2003).
Immunoglobin E is synthesised in B lymphocytes in lymph nodes or 
locally in nasal or bronchial mucosa (KleinJan et al. 2000; Takhar et al. 
2007). It has also been suggested that in some asthma and rhinitis patients 
who have no systemically detectable specific IgE or in whom no trigger-
ing antibodies have been identified, IgE may be produced locally in the 
respiratory mucosa. The production of antigen-specific IgE requires that 
such antigens are taken up by dendritic cells or other antigen-presenting 
cells (Burton et al. 2011; Galli et al. 2012) and are presented to Th2 
cells. Th2 cells or other cells then secrete IL-4 and IL-13 which induces 
B cells to undergo a class-switch recombination. It binds to mast cells, 
basophils and eosinophils facilitating allergen-specific activation of these 
cells. This has been shown to extend mast cell survival. IgE can also bind 
to dendritic cells and facilitate the allergen uptake for processing and 
presentation, and to monocyte macrophages and B lymphocytes.
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2.5  nonallergic components of the    
 pathogenesis of asthma and rhinitis
2.5.1  inflammation in asthma
Over the past 30 years, it has been believed that asthma is mainly caused 
by Th1-Th2 imbalance and categorized by eosinophilic inflammation 
and airway hyperresponsiveness. However, in recent years the knowl-
edge with regard to the asthmatic inflammation has increased. A strong 
innate immune component is seen in asthma and the important role 
of epithelium has become evident. In a recent study, the Th2-biased 
response was detected in only half of the asthma patients (Woodruff et 
al. 2009). In addition, Th2 cytokine inhibitors have been beneficial for 
only small subset of patients (Nair et al. 2009). It has been proposed 
that noneosinophilic asthma is a distinct clinical and pathophysiological 
phenotype and that the innate immune pathway may play a role in the 
airway inflammation of this phenotype (Haldar et al. 2007).
Airway epithelium responds to environmental substances includ-
ing pathogens, allergens, cigarette smoke and pollution. They interact 
directly with the environment and may be activated by pathogens and 
endotoxins through pattern recognition receptors and trigger or enhance 
allergic response. In addition, epithelial cells secrete inflammatory me-
diators such as IL-25, epithelial cytokines and chemokines, participate 
in host defence and maintain chronic inflammation (Fahy et al. 2011; 
Holgate 2011). 
Neutrophils are present in airway inflammation in several types of 
asthma, and in some asthmatics they are the predominant inflammatory 
cells (Jatakanon et al. 1999). Presence of neutrophils is associated with 
a worse asthma outcome and inhaled corticosteroids are less effective in 
these asthma patients. Neutrophils may be recruited to the airways by 
IL-17 and they may participate in the airway inflammation by releasing 
reactive oxygen species, cytokines, lipid mediators and enzymes (Bor-
regaard et al. 1997).
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2.5.2  Pathogenesis of nonallergic rhinitis
Nonallergic rhinitis is a heterogeneous condition, and the underlying 
mechanisms are not completely understood. In a subgroup of subjects 
with nonallergic rhinitis, inflammation have been detected in the nasal 
mucosa. In patients suffering from nonallergic rhinitis with eosinophilia 
syndrome, increased numbers of eosinophils and mast cells have been seen 
in the nasal biopsies (Powe et al. 2001). In some subjects, predominant 
neutrophilic or mast cell infiltrate can be detected (Maselli Del Giudice 
et al. 2012). The pathophysiology of local allergic rhinitis is characterised 
by local production of specific IgE and Th2 cytokine pattern of mucosal 
cell infiltration (Rondón et al.2009).
Subjects with the noninflammatory form of nonallergic rhinitis are 
often hyperresponsive to the physical and chemical stimuli such as cold 
air and strong odours. This may be related to the increase in C-fiber 
activity (Garay 2004). C-fibers are unmyelinated sensory neurons that 
innervate vessels, glands and epithelium of nasal mucosa. On stimulation 
they release neuropeptides such as substance P and calsitonin gene-related 
protein, leading to increased vascular permeability and nasal secretion.
It has been demonstrated that subjects with nonallergic rhinitis have 
abnormalities in the autonomic nervous system testing, suggesting an 
imbalance between the parasympathetic and sympathetic system, or 
hyporeactivity of the sympathetic system (Jaradeh et al. 2000). In the 
case of cold induced nasal blockage, a hyperactive afferent cholinergic 
parasympathetic reflex arc has been detected (Silvers 1991).
2.6  microRnAs
The immune system is controlled by the dynamic and multilevel regula-
tion of gene expression in each cell type. Gene expression can be regulated 
at different levels, from the initiation of the transcription, through RNA 
processing to the post-translational modification. miRNAs constitute a 
group of gene expression regulators that post-transcriptionally fine-tune 
the expression of genes. 
In 1993, the first miRNA, named lin-4, was identified in nematode 
Caenorhabditis elegans (Lee et al. 1993). Seven years later the second 
miRNA, let-7 was detected in the same species (Reinhart et al. 2000). 
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Following this, a large-scale scale screening and identification of new 
miRNAs began. Currently, more than 1800 human miRNA sequences 
are annotated in the miRNA database miRBase. The term “microRNA” 
was first used in 2001 by Reinhart and colleagues (Lagos-Quintana et 
al. 2001). 
miRNAs are small, 19‒25 nucleotides long, single-stranded RNA 
molecules. They are synthetized in nucleus by RNA polymerase II as 
longer transcripts called pri-miRNAs. Subsequently, pri-miRNAs are 
cleaved to small hairpin-like precursors called pre-miRNAs. Pre-miRNAs 
are exported to the cytoplasm where thy undergo processing by the en-
zyme Dicer and the generation a short RNA duplex (Bartel 2004). They 
bind to 3’ untranslated region of target messenger RNA (mRNA) and 
cause gene silencing mainly through degradation of target mRNAs or by 
inhibition of translation (Guo et al. 2010). They do not switch off the 
expression of their target genes, but reduce the amount of mRNA and 
protein. Expression of miRNA is often tissue specific. miRNAs form a 
complex network; one miRNA can target hundreds of genes and a single 
gene is typically targeted by multiple miRNAs. They regulate a wide va-
riety of functions including cell proliferation, apoptosis, stress response 
and immune response (Winter et al. 2009). Several diseases, such as 
many cancers, metabolic diseases and inflammatory diseases, have been 
associated with deregulated miRNA expression (Lu et al. 2005; Krutzfeldt 
et al. 2006; Lu et al. 2009a). The first miRNA-based drugs are already 
at the clinical trial stage: anti-miR-122 oligonucleotide drug has been 
tested for hepatitis C virus infection treatment and liposome-formulated 
miR-34 mimic is being tested for patients with advanced hepatocellular 
cancer (Lanford et al. 2010; Ling et al. 2013).
Recently, the role of miRNAs in allergic airway diseases has been 
studied in clinical settings. The expression of one or several predeter-
mined miRNAs, or a panel of several hundreds of miRNAs can be 
detected from one sample. In 2009, Williams and colleagues (2009) 
determined the expression of 227 miRNAs in the bronchial biopsies of 
eight mild asthmatics and eight healthy controls. They found no differ-
ence in miRNA expressions between these groups and no changes were 
detected in the expressions after inhaled steroid treatment of asthmatics. 
In contrast, Jardim and colleagues (2012) compared bronchial epithelial 
cells of 16 asthmatics and 16 healthy controls and found 66 differentially 
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expressed miRNAs. In addition, Solberg and colleagues (Solberg et al. 
2012) examined bronchial epithelial cells of steroid naïve asthmatics and 
found a markedly abnormal pattern of miRNA expression in most of 
the asthmatics; altogether 217 miRNAs were differentially expressed in 
the asthmatics. They also studied asthmatics using inhaled steroids and 
found that inhaled steroids only had a modest effect on these alterations. 
The discrepancy between the study by Williams colleagues and the more 
recent studies may be explained by different samples. Williams and col-
leagues studied miRNA expression in bronchial biopsies, whereas in the 
more recent studies cultured epithelial cells were investigated. 
In addition to bronchial cell miRNA expressions, other biological 
samples of asthmatics have been studied. Liu and colleagues (2012) iden-
tified upregulation of miR-221 and miR-485-3p in the blood samples 
of six asthmatic children compared to six healthy controls. Tsitsiou and 
colleagues (2012) found reduced levels of miR-146a/b and miR-28-5p 
in circulating lymphocytes of patients with severe asthma. It has recently 
been demonstrated, that the levels of certain miRNAs including miR-21, 
miR-155 and let-7a are decreased in the exhaled breath condensate of 
asthmatics when compared to controls (Pinkerton et al. 2013). In ad-
dition, 24 miRNAs, including members of let-7 and miR-200 families, 
have been differentially expressed in the broncholveolar lavage fluid 
exosomes in the asthma patients when compared to the healthy controls 
(Levanen et al. 2013). 
There are few clinical studies of miRNA expression changes in allergic 
rhinitis patients. Shaoquing and colleagues (2011) studied nasal biopsy 
samples of eight patients with allergic rhinitis and eight healthy controls. 
In the microarray chip of 421 miRNAs, nine miRNAs had more than 
two-fold change in expression, two miRNAs were up-regulated and seven 
down-regulated. In another study, a reduced level of miR-21 in human 
umbrical blood mononuclear leukocytes was associated with antenatal 
IgE production and development of allergic rhinitis (Chen et al. 2010). 
The functional role of the miRNA in allergic diseases has been studied 
extensively in mouse models and in cultured cell lines. These studies have 
revealed the importance of some miRNAs in allergic airways diseases, 
as listed in Table 1. In allergic asthma models, miR-21 has been overex-
pressed in the lung tissue, the highest levels localized in the macrophages 
and dendritic cells. Moreover, it has been found to modulate IL-12 
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expression (Lu et al. 2009b). In the ovalbumin induced asthma model, 
miR-21 deficient mice had reduced lung eosinophilia, and increased 
INF-γ level and reduced IL-4 level in bronchoalveolar lavage following an 
allergen challenge (Lu et al. 2011). In addition, miR-21 was upregulated 
in the human epithelial cells after IL-13 treatment (Case et al. 2011). 
Let-7 family miRNAs have been shown to influence the expression of 
IL-13 in the lung epithelial cell line (Kumar et al. 2011). The intranasal 
administration of let-7 led to a reduced IL-13 level and reduced bronchial 
hyperresponsiveness as well as the resolution of allergic inflammation in 
the ovalbumin-induced mouse model. In contrast, the let-7 inhibitor 
inhibited the production of allergic cytokines and disease phenotype 
in the mouse model (Polikepahad et al. 2010). In the acute house dust 
mite-induced asthma model, miR-126 was upregulated, and inhibition 
of miR-126 reduced the asthmatic response (Mattes et al. 2009). In 
addition, miR-126 was up-regulated two weeks after an allergen chal-
lenge (Collison et al. 2011a). miR-155 has been shown to modulate the 
response of human macrophages to IL-13 and is thus essential in the 
acquisition and maintenance of a Th2 phenotype (Martinez-Nunez et al. 
2011). Malmhäll and colleagues (2014) found that miR-155 deficiency 
resulted in diminished eosinophilic inflammation and Th2 cytokine 
levels in the mouse model. 
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Table 1. List of some essential microRNAs and their function in 
allergic airway inflammation.
miRNA Function Reference
miR-21 Upregulated in lung-specific IL-13 expressing 
transgenic mice with induced allergic airway 
inflammation.
(Lu et al. 
2009b)
Overexpression reduced TLR2 antagonist-induced 
lung inflammation in mice. 
(Case et al. 
2011) 
miR-21 deficiency increased Th1 cytokine levels 
and reduced eosinophilia in an ovalbumin-
induced mouse model of asthma. 
(Lu et al. 
2011)
Reduced level in umbrical blood leucocytes 
associated with development of allergic rhinitis. 
(Chen et al. 
2010)
let-7 family Overexpression reduced allergic inflammation in 
OVA induced mouse model of asthma.
(Kumar et al. 
2011)
let-7 inhibitor inhibited the production of allergic 
cytokines and disease phenotype in mouse 
model.
(Polikepahad 
et al. 2010)
miR-126 Silencing reduced allergic inflammation in 
a house dust mite induced mouse model of 
asthma.
(Mattes et al. 
2009)
Reduced eosinophilia in the mouse model of 
chronic airway inflammation.
(Collison et al. 
2011a)
miR-155 Required for Th2 mediated eosinophilic 
inflammation in the ovalbumin-induced mouse 
model of asthma.
(Malmhall et 
al. 2014)
miR-155-deficient mice developed asthma-like 
inflammation in the lung.
(Rodriguez et 
al. 2007)
miR-146a Increased expression in Th2 lymphocytes in 
mouse model. 
(Feng et al. 
2012)
Reduced cytokine-induced apoptosis in human 
bronchial epithelial cells. 
(Liu et al. 
2009) 
Reduced expression in circulating Th1 and Th2 
cells in patients with severe asthma. 
(Tsitsiou et al. 
2012)
miR-145 Up-regulated in the airway wall of house dust 
mite induced mouse model of asthma and anti-
miR-145 reduced allergic inflammation.
(Collison et al. 
2011b)
miR-106a Up-regulated in the lungs of ovalbumin-induced 
mouse model of asthma, anti-miR-106 reduced 
allergic inflammation.
(Sharma et al. 
2012)
Regulates IL-10 expression. (Sharma et al. 
2009)
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2.7  nitric oxide
2.7.1  nitric oxide in the airways
Nitric oxide is a small gaseous molecule synthetized from oxygen and 
the amino acid L-arginine by the nitric oxide synthase (NOS) enzymes 
(Moncada et al. 1993). In human airways, three isoforms of NOS have 
been identified (Yates 2001). Endothelial NOS and neuronal NOS, 
referred as constitutional NOS are calsium-calmodulin dependent and 
activated in response to a calcium signal. The predominant NOS form in 
airway epithelia is inducible nitric oxide synthetase (iNOS) (Lundberg et 
al. 1995). It is calcium independent and activated by proinflammatory 
cytokines such as inteleukin-1, TNF-α, IFN-γ and bacterial lipopolysac-
charides. Up to 1000 times higher levels of nitric oxide can be produced 
by iNOS compared to constitutional NOS. Nitric oxide is produced by 
many structural and inflammatory cells including eosinophils, mast cells, 
epithelial cells, macrophages and smooth muscle cells. In the normal 
lower airways, iNOS seems to be expressed primarily in the respiratory 
epithelium.
Nitric oxide has a role in host defence in the airways because of its 
antimicrobial activities (Lundberg et al. 1999). It has also been shown 
to regulate ciliary motility (Runer et al. 1998) and it plays a role in the 
regulation of vasodilatation and neurotransmission (Lundberg et al. 
1999; Yates 2001). The continuous expression of iNOS in the normal 
miR-133a Downregulated in cultured human airway smooth 
muscle cells after IL-13 stimulation. Anti-miR-
133a in bronchial smooth muscle cells increased 
airway contraction and hyperresponsiveness.
(Chiba et al. 
2009)
miR-221 Up-regulated in ovalbumin mouse model of 
asthma.
(Qin et al. 
2012) 
Up-regulated in the peripheral blood of asthmatic 
children.
(Liu et al. 
2012)
miR-1 Down-regulated by vascular endothelial growth 
factor (VEGF) in the lung endothelium. Intranasal 
administration inhibited inflammatory responses 
to ovalbumin and house dust mite.
(Takyar et al. 
2013)
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epithelium has been suggested to be maintained by IFN-γ (Uetani et 
al. 2001). It has been proposed that nitric oxide may promote Th2 type 
inflammation because it reduces INF-γ levels and thus increases pro-
liferation of Th2 cells and Th2 type inflammation. It is also important 
in eosinophil migration and infiltration (Korhonen et al. 2005). More 
recently, it has been shown that an increase in nitric oxide in the allergic 
inflammation of the airways depends primarily on IL-4 and/or IL-13 
activity (Guo et al. 1997; Suresh et al. 2007).
Nitric oxide is produced in both the upper and lower airways. How-
ever the major source of nitric oxide is the upper airways (Lundberg et 
al. 1995; Lundberg et al. 1999). Up to 20‒100 times higher nitric oxide 
concentrations can be measured in the upper airways than in the lower 
airways. Most of the nitric oxide produced in the upper airways originates 
from the paranasal sinuses (Lundberg et al. 1995).
2.7.2  measurement 
Nitric oxide measurements are usually performed on-line, but off-line 
measurements of exhaled nitric oxide are also possible. The most com-
mon method for measuring nitric oxide has been the chemiluminence 
technique, which is based on the photochemical reaction between nitric 
oxide and ozone generated in the analyser. The result is expressed as a 
fractional concentration, parts per billion (ppb). More recently, hand 
held devises using electrochemical sensor technology have been devel-
oped. These methods show good correlation and reproducibility in both 
upper and lower airway measurements (Silkoff et al. 1999; Ekroos et al. 
2000; Ekroos et al. 2002; Alving et al. 2006; Stark et al. 2007). A rec-
ommendation for the standardisation of exhaled and nasal nitric oxide 
measurements was provided by American Thoracic Society (ATS) and 
European Respiratory Society (ERS) in 2005 (ATS/ERS 2005). 
Exhaled nitric oxide measured using a standardised procedure (ATS/
ERS 2005). Subjects inhale nitric-oxide-free air and subsequently exhale 
near-total lung capacity for at least six seconds against a flow resistor in 
order to close the soft palate to avoid contamination of the nitric oxide 
from the upper airways. The plateau concentration is defined as the 
mean concentration over three seconds during the stable end-expiratory 
plateau. The procedure is repeated at least twice, and the reproducible 
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exhalations have plateaus values that agree within 10%. The result of the 
test is the mean of the plateau values. In order to obtain reproducible 
measurements, variation of the exhalation flow rate should be small. 
The recommended flow is 50 ml/s, and during the time of the nitric 
oxide plateau generation should remain between 45‒55 ml/s. Multiple 
flow rates can be applied to differentiate between alveolar and bronchial 
components of NO output (Lehtimäki 2003). Several factors influence 
the exhaled nitric oxide levels. Smoking reduces exhaled nitric oxide 
level, whereas respiratory tract infections increase the levels (Persson et 
al. 1994; Kharitonov et al. 1995). In addition, eating nitrate-containing 
food, drinking coffee and performing spirometric manoeuvres may alter 
exhaled nitric oxide levels (Deykin et al. 1998; Olin et al. 2001; Bruce 
et al. 2002). 
Nasal nitric oxide measurement requires generation of airflow through 
the nasal cavity; velum closure is essential to prevent leakage of nitric 
oxide to the oropharynx or dilution of sample from the gas originating 
from the lower respiratory tract (ATS/ERS 2005). There is not a single 
recommended standardised method in use. In the breath-holding method 
nasal air from the nasal cavity is aspirated with a steady flow by using a na-
sal olive when the subject is holding his/her breath. In the tidal breathing 
method, nasal nitric oxide is measured during tidal breathing. The subject 
breathes with one nostril and the air is sampled from the other nostril at 
a steady flow. A modification of this method, subject breathing against 
resistance was recommended by the ATS and ERS Taskforce (ATS/ERS 
2005). The humming method, that is, the measurement of nasal nitric 
oxide during quiet phonation, has been introduced as a tool to meas-
ure osteomeatal patency. It has been reported that humming increases 
nasal nitric oxide levels 15-fold by increasing sinus ventilation and this 
increase is not detected in patients with occluded sinus ostia (Weitzberg 
et al. 2002; Lundberg et al. 2003). De Winter and colleagues (2009) 
compared different methods and concluded that the best reproducibility 
is achieved by using the breath-holding and humming methods. Nitric 
oxide concentration is calculated from the steady plateau in the nasal 
nitric oxide versus time curve, usually reached within 20 seconds. Similar 
to exhaled nitric oxide measurement, using a constant and controlled 
flow is essential. There are no reference values for nasal nitric oxide in 
adults. The values vary even in equivalent patient groups because of the 
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variation of methods, also a high level of intra-individual variation over 
time and inter-individual variation in healthy subjects have been detected 
(Kharitonov et al. 1997; Bartley et al. 1999). Nevertheless, it has been 
suggested, that the normal nasal nitric oxide range would be 450‒900 
ppb when the breath-holding method is used (Scadding et al. 2009). 
Heavy physical exercise, smoking, nasal volume and aerodynamics of 
the air flow may affect the value (Phillips et al. 1996; Olin et al. 1998; 
Colantonio et al. 2002)
2.7.3  exhaled nitric oxide in asthma and rhinitis
Alving and colleagues (1993) first demonstrated higher amount of ex-
haled nitric oxide in atopic asthma than in healthy subjects. An increase 
in iNOS expression in bronchial biopsies of asthma patients has been 
shown (Hamid et al. 1993). Exhaled nitric oxide is commonly regarded 
as a marker of eosinophilic airway inflammation, or more specifically as 
a marker of Th2-type local inflammation of the bronchial mucosa rather 
than general eosinophilic inflammation (Szefler et al. 2012; Bjermer 
et al. 2014). Exhaled nitric oxide levels are associated with eosinophil 
numbers in bronchoalveolar lavage fluid, bronchial biopsies and induced 
sputum (Jatakanon et al. 1998; Payne et al. 2001; Warke et al. 2002; 
Berry et al. 2005b). Increased levels of exhaled nitric oxide have been 
reported in subjects with allergic rhinitis without asthma diagnosis or 
asthma symptoms (Palm et al. 2003). Exhaled nitric oxide level was 
related to atopy in asthma and rhinitis patients; in subjects with asthma 
or rhinitis without positive SPTs, the exhaled nitric oxide level did not 
differ from healthy controls (Gratziou et al. 1999). However, in the 
study by Rouhos and colleagues (2008) atopic sensitization without 
airway diseases or symptoms did not increase the exhaled nitric oxide 
level. The association with markers of eosinophilic inflammation is lost 
in smokers (Berry et al. 2005b). 
Numerous studies have examined the feasibility of exhaled nitric 
oxide in asthma phenotyping and monitoring. The ATS/ERS Statement 
recommended that “clinical utility of exhaled nitric oxide based strategies 
have not been explored extensively. Current available evidence suggest a 
role in identifying the phenotype in airways disease, particularly in the 
identification of corticosteroid responsiveness” (Reddel et al. 2009). More 
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recently, ATS guidelines recommended the use of exhaled nitric oxide 
in monitoring airway inflammation in patients with asthma (Dweik et 
al. 2011).
Recent studies have evaluated exhaled nitric oxide levels measured 
using different flow rates in asthma patients. Lehtimäki and colleagues 
(2002) originally showed that subjects with nocturnal asthma symptoms 
had higher alveolar nitric oxide levels compared to asthma patients 
without nocturnal symptoms and to healthy controls. It has also been 
shown that alveolar nitric oxide levels correlate with small airway func-
tion in severe asthma (van Veen et al. 2006), and that the alveolar nitric 
oxide levels correlate with the eosinophil count in brochoalveolar lavage, 
but not with sputum or bronchial wash eosinophils of asthma patients 
(Berry et al. 2005a).
2.7.4 nasal nitric oxide in allergic rhinitis
Increased levels of iNOS have been detected in nasal epithelial cells of 
allergic rhinitis patients (Kawamoto et al. 1999; Takeno et al. 2001), 
similar to those detected in the bronchial biopsies of asthma patients 
(Hamid et al. 1993). Studies of nasal nitric oxide levels in allergic rhini-
tis are controversial. Kharitonow and colleagues (1997) found that the 
nasal nitric oxide level was significantly elevated in the symptomatic 
allergic rhinitis patients compared to the healthy controls. Similarly, 
in the study of Arnial and colleagues (1997) the nasal nitric oxide level 
was significantly higher in the subjects with allergic rhinitis than in the 
controls. The nasal nitric oxide level was increased also in those allergic 
rhinitis patients who did not have rhinitis symptoms on the day of the 
test. Other studies have shown contradictory results (Henriksen et al. 
1999; Palm et al. 2003). In these studies the level of nasal nitric oxide 
was not significantly increased in the subjects with seasonal allergic 
rhinitis examined during the pollen season. It has been postulated that 
these controversial results may be explained by the nitric oxide pathway. 
In the inflammatory conditions cytokines might induce increased activ-
ity of arginase causing reducing bioavailability of L-arginine for iNOS 
(Meurs et al. 2000). Maniscalco and colleagues (2010) have proposed 
that “while nitric oxide release from the inflamed nasal mucosa might 
be increased, at the same time the swelling of the nasal mucosa may lead 
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to obstruction of the sinus ostia, with less influx of nitric oxide from the 
sinuses to the nasal cavity, where the nitric oxide is being measured”. In 
most of the studies described above, sinus diseases were not excluded 
from the study population. 
2.8  induced sputum 
2.8.1  method
In 1992, the induced sputum method was introduced to assess airway 
inflammation in asthma (Pin et al. 1992b). The method of sputum in-
duction with hypertonic saline and processing has been covered by ERS 
Task Force in 2002 (Djukanovic et al. 2002; Efthimiadis et al. 2002; 
Paggiaro et al. 2002). Hypertonic saliva used sputum induction may 
cause bronchial obstruction. It is regarded as a safe method when it is 
performed after bronchodilating medication and lung function, usu-
ally PEF, is assessed before and after the induction (Wong et al. 1997). 
The two main methods for sputum processing are in use. In the whole 
expectorate method the entire sputum expectorate is usually mixed with 
dithiothreitol (DTT) to reduce disufide bonds in mucus, then homog-
enized, filtered and finally centrifuged to separate cells and fluid phase. 
In the sputum plug method mucous plugs are selected using a wooden 
spatula and the mucous plug material is processed forward similar to the 
other method. Different methods used for sputum processing may cause 
differences in the results between the studies. However, in the studies 
comparing these methods, similar findings in sputum eosinophils and 
ECP levels have been found (Gershman et al. 1996; Szefler et al. 2012). 
One of the greatest limitations of the induced sputum method is the 
difficulty in achieving suitable samples from a substantial proportion of 
the patients (Matsuoka et al. 2008). Nevertheless, it has been reported 
that with experienced personnel sputum can be obtained from 80‒90% 
of the patients (Belda et al. 2000; Spanevello et al. 2000). The short term 
repeatability of induced sputum cell analysis and liquid phase markers 
is good both in healthy subjects and in asthma patients (Purokivi et al. 
2000; Fahy et al. 2001). 
The sputum cell count is usually reported as the percentage of non-
squamous cells in the sample. Squamous cells are also counted to deter-
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mine sample quality. A squamous cell percentage of greater than 80% is 
taken to indicate inadequate quality of the sputum sample (Fahy et al. 
1993). The sputum cell count is a well-validated method for assessing 
cellular inflammation in the airways (Szefler et al. 2012). It has been 
shown to reflect the findings in bronchial wash and bronchoalveolar 
wash samples (Fahy et al. 1995b). 
Several biomarkers have been detected in the induced sputum fluid-
phase or supernatant of the asthma patients (Dragonieri et al. 2009). 
However, the validity and reproducibility of techniques to detect fluid-
phase markers are not assessed as well as that of the sputum cell analysis, 
and certain factors (e.g. DTT, proteases in the sputum) may hamper 
analyses of some of the markers (Efthimiadis et al. 1997; Kelly et al. 
2000; Stockley et al. 2000).
2.8.2  findings in asthma and allergic rhinitis
Sputum eosinophilia has been recognized as a characteristic feature of 
asthma and shown to predict the response to corticosteroid treatment 
for more than 50 years (Brown 1958). The eosinophil percentage is 
related to the airflow obstruction and bronchial hyperresponsiveness 
in asthmatics, the inverse relationship between the sputum eosinophil 
percentage and FEV1 as well as the sputum eosinophil percentage and 
provocative concentration causing a 20% fall in FEV1 to metacholine 
has been observed (Woodruff et al. 2001). The eosinophil count rise in 
response to the allergen challenge and fall in response to the corticos-
teroid treatment in asthma (Pin et al. 1992a; Claman et al. 1994). In 
addition, an increase in the sputum eosinophil count predicts the loss 
of asthma control (Deykin et al. 2005; Jayaram et al. 2006). An increase 
in the sputum eosinophil count has also been detected in patients with 
seasonal allergic rhinitis without asthma (Foresi et al. 1997). The ATS/
ERS statement on asthma control and exacerbations concluded that “eo-
sinophil assessment in sputum provides additional, clinically important 
information about inhaled corticosteroid responsiveness and preventable 
future risk of exacerbations” (Reddel et al. 2009). 
Sputum neutrophilia is a common finding in adult asthma patients 
with persistent asthma (Gibson et al. 2001). It is also related to severe 
airway obstruction in asthma; an inverse correlation between sputum 
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neutrophil count and FEV1 has been detected (Woodruff et al. 2001). 
Moreover, an increase in the sputum neutrophil count is seen in asthma 
exacerbations (Fahy et al. 1995a). Recently, Moore et al. used cluster 
analysis for over 400 subjects and found that sputum neutrophilia was 
associated with more severe asthma (Moore et al. 2013).
On the basis of the sputum cell inflammatory profile, asthmatic 
subjects can be categorised into four groups: eosinophilic (sputum 
eosinophils ≥2%), neutrophilic (sputum neutrophils >61%), mixed 
granulocytic (sputum eosinophils ≥2% and neutrophils >61%), pauci-
granolocytic type (both eosinophils and neutrophils in normal range) 
(Simpson et al. 2006; Davies et al. 2013). Sputum inflammatory profiles 
have been used in phenotyping and endotyping asthma patients. How-
ever, recent studies have suggested that the sputum inflammatory profile 
commonly changes in asthmatics. During a one year follow-up, stabile 
phenotypes were detected in only one third of subjects with moderate 
and severe asthma (Al-Samri et al. 2010). 
In the fluid phase of sputum, ECP and myeloperoxidase have shown 
to correlate with eosinophil count in asthmatics (Efthimiadis et al. 1997). 
The level of IL-8, a chemoatractant of neutrophils has been shown to be 
elevated in persistent neutrophilic asthma and to associate with sputum 
neutrophil levels (Gibson et al. 2001). The level of Th2-type cytokine 
IL-13 has also been found to be elevated in some asthma patients (Saha et 
al. 2008). Also, Cys-LTs have been increased in asthma patients (Pavord et 
al. 1999). Recently, the levels of both vascular endothelial growth factor 
(VEGF) and Cys-LTs were shown to be elevated in asthma and the levels 
were highest in severe asthma group (Papadaki et al. 2013). In addition, 
elevated levels of albumin, fibrinogen, nonkinase plasminogen activa-
tor, plasminogen activator inhibitor, neurokinin A, 8-isoprostane and 
matrix metalloproteinasis-9/tissue inhibitor of metalloproteinases rate 
have been found in the fluid-phase of sputum (Dragonieri et al. 2009).
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2.9 nasal lavage fluid
2.9.1  method
Proteins and cells cleared from the mucosa tissue of the airways are con-
sidered to end up mainly in the airway lumen (Howarth et al. 2005). 
Nasal lavage is a simple and well tolerated method to investigate nasal 
inflammation. It is performed by instilling physiologic solution in the 
nasal cavity and collecting the recovered fluid. Several nasal lavage tech-
niques can be used. In the Naclerio method, subjects sit with their neck 
extended backward and hold their breath when instilling the fluid and 
after 10 seconds the subject leans forward and expels the fluid into the 
container (Naclerio et al. 1983). In Greiff’s method, later modified by 
Grunberg, fluid is introduced with the catheter into anterior part of the 
nose with the neck flexed forward, with the seal at the anterior nares 
around the administrative device to prevent the fluid coming out (Greiff 
et al. 1990; Grunberg et al. 1997). The volume of instilled liquid is usu-
ally 2.5‒10 ml, with approximately 80% recovery. After collection, the 
fluid is filtered and centrifuged to separate cells and supernatant. The cell 
pellet can be suspended in phosphate buffered saline to make microscopic 
slides for differential cell counts and immunostaining. The repeatability 
of this test is considered good when evaluating eosinophil count (Belda 
et al. 2001). However, marked variability in the soluble inflammatory 
mediators has been detected, and the level of several mediators has been 
low or undetectable (Roponen et al. 2003; Boot et al. 2008). Neverthe-
less, significant differences in the levels of inflammatory mediators has 
been found between healthy subjects and subjects with allergic rhinitis.
2.9.2  findings in allergic rhinitis and asthma
Nasal lavage fluid has been used to examine nasal inflammation in 
naturally occurring allergic rhinitis (Howarth et al. 2005). Increased 
eosinophil counts as well as elevated levels of eosinophil activation 
markers, ECP and Eosinophil protein X (EPX) have been detected in 
allergic rhinitis patients compared to healthy controls (Svensson et al. 
1990; Knani et al. 1992; Di Lorenzo et al. 1997; Wilson et al. 1998). 
In addition, levels of markers related to basophil activation, tryptase and 
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PGD2, PGE2 and LT levels have been aggravated in these subjects (Vo-
lovitz et al. 1988; Knani et al. 1992; Sugimoto et al. 1994; Di Lorenzo 
et al. 1997; Wilson et al. 1998). Elevated levels of plasma exudation 
markers have also been found in allergic rhinitis; an increase in albumin 
levels have been detected in these patients compared to healthy subjects 
and an increase in the level of α2 makroglobulin during pollen season 
in seasonal allergic rhinitis has been seen (Svensson et al. 1990; Wilson 
et al. 1998). More recently, Amorom and colleagues showed that lavage 
fluid eosinophil counts are good predictors of sputum eosinophilia in 
asthma patients (Amorim et al. 2010). Nasal lavage fluid has also been 
widely used to study mechanisms of underlying responses to intranasal 
allergen challenge as well as to challenges with certain stimuli includ-
ing histamine and methacoline, capsaisin, bradykinin and substace P 
(Howarth et al. 2005).
2.10 Proteomics
Proteomics is an unbiased method to investigate the entire protein 
content of the sample, for example, cell, tissue or biofluids, at a certain 
time point (Coombs 2011). This method utilizes many technologies, 
including protein extraction and sample fractionation, protein and pep-
tide separation, mass spectrometry to determine the molecular mass of 
proteins, protein identification and the enrichment analysis of identified 
proteins. The term proteomics was first introduced in 1995; since then 
progress in the proteomic field has been rapid, and new mass spectrom-
etry techniques and software for protein identification and expression 
analysis have been introduced. Proteomics adds information to genetic 
studies, which are unable to determine whether genes or mRNAs end 
up being functional proteins. It provides a sensitive tool to detect disease 
biomarkers and obtain information on protein interactions, the extent 
of post-translational modifications that contribute to protein function 
and quantity of a protein in the sample. 
2.10.1 Sputum proteomics
During recent years, induced sputum biomarkers have been investigated 
using proteomics (Wheelock et al. 2013; Viglio et al. 2014). Gray and 
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colleagues (2008) studied induced sputum samples from 20 healthy 
controls, 24 subjects with asthma, 24 subjects with chronic obstructive 
pulmonary disease and 28 with cystic fibrosis. Altogether 105 proteins 
differentiated significantly in the asthma group compared to healthy 
controls, and eight of these were identified and confirmed. Gharib and 
colleagues (2011) reported induced sputum protein abundance identi-
fication and quantification and function annotation from five healthy 
controls and ten asthmatic subjects. They identified altogether 254 
proteins in the healthy controls and asthmatics and 17 differentially 
expressed proteins between these groups. These proteins were associ-
ated with protease inhibitory activity, defence response, immunity and 
inflammation. This method robustly differentiated asthmatics from 
healthy controls. Lee and colleagues (2013) studied sputum samples of 
subjects with severe asthma and neutrophilic inflammation with prot-
eomics. They found 13 differentially expressed proteins in the subjects 
with uncontrolled asthma compared to those with controlled asthma. 
S100 calcium binding protein A9 was detected to be increased in severe 
uncontrolled asthma with neutrophilic inflammation.
2.10.2 nasal lavage fluid proteomics 
Similar to induced sputum proteomic studies with asthmatics, the pro-
teomics method has been utilized to study nasal lavage fluid biomarkers 
in allergic rhinitis. Ghafouri and colleagues (2006) examined the nasal 
lavage fluid proteome of six patients with seasonal allergic rhinitis and six 
healthy controls before and during pollen season. They found changed 
levels of several proteins including one formerly unidentified protein in 
nasal lavage fluid in the allergic rhinitis patients during pollen season. 
In addition, one protein (acidic form of α1-antitrypsin) was increased 
in allergic rhinitis patients also outside pollen season. Benson and col-
leagues (2009) studied nine patients with allergic rhinitis and six patients 
with chronic rhinosinusitis combined with asthma. They identified 197 
proteins in the nasal lavage fluid and detected differences in the protein 
abundances between these two groups. More recently, Wang and col-
leagues (2011a; 2011b) published two reports on biomarkers related 
to the effect of glucocorticoid treatment in seasonal allergic rhinitis. In 
addition to the proteomic analysis of nasal lavage fluid, nasal lavage fluid 
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cells and biopsies from the nasal mucosa were studied using microarray 
analysis. They found many new biomarkers for glucocorticoid treatment 
and showed that it affected wide variety of pathways in allergic rhinitis. 
A significant change in the expression of several proteins formerly not 
identified in allergic rhinitis was also detected.
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3  AimS of tHe StuDy
The aim of this thesis was to study airway inflammation biomarkers in 
asthma and rhinitis in the context of united airway disease hypothesis.
The more specific objectives were:
1. To determine whether airway inflammation and miRNA levels in 
nasal mucosa differs in symptomatic and non-symptomatic subjects 
with allergic or nonallergic rhinitis and to examine whether con-
comitant asthma has an effect on airway inflammation in allergic 
rhinitis (Study I).
2. To detect potential biomarkers in nasal mucosa related to long term 
asthma and allergic rhinitis and evaluate whether these markers 
differ between asthmatics with and without rhinitis or in terms of 
asthma severity (Study II). 
3. To evaluate the association between sinus ostial obstruction and the 
level of nasal nitric oxide, and the association between nasal nitric 
oxide and exhaled nitric oxide, sinus opacification, nasal mucosal 
eosinophilia and Th2-type cytokine levels (Study III).
4. To study the induced sputum proteome of subjects with asthma 
and rhinitis and to identify differentially expressed proteins and 
thus potential candidate biomarkers that could be found both in 
the upper and lower airways (Study IV).
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4  mAteRiAlS AnD metHoDS
4.1  Subjects and study design
4.1.1  Study population A (i, iii, iv)
Study population A comprised of Finnish men and women, who were 
first year students in Finnish Universities in 1995, aged 18 to 25 years, 
and took part in a baseline questionnaire study on asthma and allergic 
diseases and their risk factors. The population is described in detail in 
the articles of Kilpeläinen and colleagues (2000; 2001a; 2001b; 2002a; 
2002b; 2006). A twelve-year follow up study of all participants of the 
baseline study was performed in 2007, using the same diagnostic ques-
tions of asthma, allergic and non-allergic rhinitis. The responders were 
divided into four groups according to the postal questionnaire answers. 
The allergic rhinitis group had positive answer to the question of 
physician-diagnosed allergic rhinitis and negative answers to the ques-
tions on asthma or physician-diagnosed asthma. The allergic rhinitis 
and asthma group had positive answers to the questions of physician-
diagnosed asthma and allergic rhinitis. The nonallergic rhinitis group 
had a positive answer to the question “Have you ever had, recurrently 
or for a longer period of time, nasal symptoms (such as blocked nose, 
sneezing, nasal discharge) that are not related to a common cold or other 
respiratory infection?”, and negative answers to the questions on allergic 
rhinitis and physician-diagnosed allergic rhinitis. The control group had 
negative answers to the questions concerning nasal symptoms and al-
lergic rhinitis diagnosis, allergic conjunctivitis symptoms and diagnosis, 
physician-diagnosed atopic dermatitis and asthma diagnosis. They also 
answered no to the question “Have you ever had attacks of breathless-
ness with wheezing?”.
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A sample of respondents from each group was randomly selected 
to take part in clinical testing at the Finnish Institute of Occupational 
Health and Turku University Central Hospital according to the postal 
code. The study design is presented in Figure 1.
After the clinical examination, each subject’s group was revised. 
Subjects in the allergic rhinitis group had one or more positive SPTs to 
common environmental aeroallergens and rhinitis symptoms related to 
exposure to the allergen to which they were sensitized. Subjects in the al-
lergic rhinitis and asthma group fulfilled the criteria of the allergic rhinitis 
group. In addition, they had previous physician-diagnosed asthma or a 
significant (≥12%) increase in FEV1 after bronchodilator administration 
and asthma symptoms. The nonallergic rhinitis group comprised subjects 
with periodic or perennial rhinitis symptoms. However, they had no 
positive SPTs to common aeroallergens or in cases of positive SPTs, they 
had no respiratory symptoms related to the allergens tested prick posi-
tive. Subjects in the control group did not have respiratory diseases, nor 
recurrent or constant respiratory symptoms. They did not have positive 
SPTs to common aeroallergens or in cases of positive tests, no respiratory 
symptoms related to the allergens tested positive. A total of 179 subjects 
participated the clinical examinations. After the examinations, the control 
group consisted of 42 subjects, the allergic rhinitis group of 52 subjects, 
the allergic rhinitis and asthma group of 40 subjects and the nonaller-
gic rhinitis group of 44 subjects. One subject with nonallergic asthma 
without rhinitis symptoms did not fulfil the criteria for any group. The 
subjects were further divided into two subgroups: subjects with current 
rhinitis symptoms and subjects without current symptoms. In Study III 
the allergic rhinitis group and the allergic rhinitis and asthma group were 
combined and analysed as one allergic rhinitis group.
56
4 material and methods
Figure 1. Description of Study population A and the clinical examinations 
(Studies I, III, IV).
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4.1.2  Study population b (ii)
The subjects in Study population B (Study II) were men who had per-
formed their military service between 1986 and 1997. The subjects in 
the asthma group had been referred to the Central Military Hospital 
in 1987‒1990 due to a diagnosis of asthma or symptoms suggestive of 
asthma. One or more of the following asthma criteria were met by the 
participants during their time of hospitalisation: a significant reversibil-
ity of bronchial obstruction in spirometry (12% and 200ml in FEV1), 
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airway hyperresponsiveness detected in the histamine challenge (dose of 
histamine causing a 15% decrease in FEV1 or PEF ≤ 0.39 mg), a positive 
exercise test (a decrease of at least 15% in PEF in the 30-minute follow-up 
after exercise), PEF recording showing repeated significant bronchodi-
lation responses (≥15%) or significant daily variation (≥20%) at least 
three times or evidence of the earlier diagnosis of asthma (Lindström et 
al. 2012). A subset of subjects had borderline diagnostic findings. The 
Finnish Defence Force 
Register 
Asthma  
 treated in Central 
Military Hospital  
1987–1990 
n=505 
 
Controls 
Entered military service 
without asthma 
1986–1990 
n=1500 
 
Questionnaire 2009 
 
Responders  
n=232 
Responders 
n=606 
Clinical Examination 
2009–2010  
n= 123 
Clinical Examination 
2010–2011 
n= 34 
Questionnaire 
Spirometry, nasal and exhaled nitric oxide 
Induced sputum, nasal lavage fluid, nasal biopsy 
Skin prick tests 
Blood sample 
Figure 2. Description of Study population B and the clinical examinations 
(Study II).
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control group consisted of men who entered their military service in 
1986‒1990 without asthma, and asthma was not diagnosed during their 
military service. The study subjects responded to the postal question-
naire sent out in spring 2009, described in detail in the publications of 
Lindström and colleagues (2011; 2012; 2013a; 2013b). The flowchart 
describing Study population B is shown in Figure 2. A total of 123 sub-
jects in the asthma group and 34 subjects in the control group partici-
pated the clinical examinations. Based on postal questionnaire answers 
subjects with allergic rhinitis or asthma were excluded from the control 
group. Subjects with asthma were analysed in the subgroups of differ-
ent asthma severities as well as in terms of concomitant allergic rhinitis.
4.2  classification of asthma (ii)
Current asthma severity was assessed using a combination of GINA 
2002 classifications of symptoms and FEV1 and current medications as 
described by Liard and colleagues (2000). Clinical severity was classified 
on four grades based on the frequency of nocturnal and diurnal symptoms 
during the past 12 months and the prebrochodilator FEV1 percentage 
of the predicted value (Lindström et al. 2012). Asthma treatment was 
classified on four grades based on daily medication use. Asthma severity 
was a combination of clinical severity and asthma treatment classifica-
tions, categories were 1) remission, 2) intermittent, 3) mild persistent, 
4) moderate persistent and 5) severe persistent. These categories were 
combined in the analysis as follows: nonpersistent asthma included asthma 
remission and intermittent asthma, persistent asthma included mild, 
moderate and severe persistent asthma.
4.3  clinical methods
In Study population A, the clinical examinations were carried out at the 
Finnish Institute of Occupational Health and at Turku University Central 
Hospital in 2008‒2009. In Study population B, the subjects were investi-
gated in 2009‒2011 at the Finnish Institute of Occupational Health. All 
participants were interviewed and examined by a physician specialised in 
ear, nose and throat diseases and a specialist in respiratory diseases. 
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4.3.1  Questionnaire
All the subjects completed in a questionnaire including questions about 
their medical history, respiratory symptoms, medication and smoking. 
They also filled a VAS scale of the severity of nasal symptoms with the 
separate scales for symptoms of rhinorrhoea, nasal congestion and nasal 
itchiness. VAS scale was a 10 cm line in which the subjects marked the 
severity of their nasal symptoms. 0 cm stood for no symptoms and 10 
cm for very severe symptoms. 
4.3.2  Skin prick tests
SPTs were performed using both a negative control and histamine as a 
positive control. A panel of birch, alder, timothy grass and mugwort pol-
len, Alternaria alternata, cat, dog and house dust mite Dermatophagoides 
pteronyssimus were tested in both populations. In addition, Aspergillus 
fumigatus and horse epithelium were tested in Study population A and 
meadow fescue, orchard grass and Cladosporium herbarum were tested in 
Study population B (ALK-Abello, Nieuwegein, the Netherlands). A wheal 
diameter of ≥3 mm was considered positive. In case of dermographismus 
(the wheal of negative control was ≥2 mm) existed, the SPT was not accepted 
for evaluation and the subject was tested with specific IgE to aeroallergens. 
4.2.3  ige
We measured serum total IgE and specific IgE to common environmen-
tal allergens with Phadia UniCAP system (Phadia, Uppsala, Sweden). 
Specific IgE was measured to specific allergen (birtch, timothy grass, cat) 
in cases of dermographismus in SPT. The result of specific IgE <0.35 
kU/l was regarded as normal.
4.3.4 Spirometry
Lung function was measured with flow volume spirometry combined 
with a bronchodilation test by using a standard spirometer (Spirostar 
USB Medikro, Kuopio, Finland). The test was performed according to 
the ATS and ERS guidelines (Miller et al. 2005) and interpreted using 
the predictive values assessed for the Finnish population (Viljanen 1982).
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4.3.5 exhaled and nasal nitric oxide
An on-line chemiluminescence analyser equipped with nasal nitric oxide 
software (NIOX, Aerocrine AB, Solna, Sweden) was used to measure 
exhaled and nasal nitric oxide. The measurements were performed ac-
cording to the ATS and ERS recommendations (ATS/ERS 2005).
Exhaled nitric oxide was measured while the subjects exhaled against 
a flow resistor slowly from total lung capacity. The exhalation flow was 
50 ml/s. The mean value was recorded for a three-second period from 
the end-exhaled nitric oxide plateau. The mean value of two or three 
consecutive measurements within 10% or 2.5 ppb variation was used 
in the analysis.
Nasal nitric oxide was measured from the nostril while the subject was 
holding his/her breath for 40 seconds. The aspiration flow was 5 ml/s. 
The value was recorded from the nitric oxide plateau and the mean value 
was calculated similar to the exhaled nitric oxide of the measurements 
within the range of 10%.
4.3.6 nasal ct (iii)
Computed tomography (CT) of the nasal region was obtained from 
Study population A. Both coronal and axial scans were obtained from 
the subjects examined at Turku University Central Hospital and coronary 
scan was obtained from the group of patients examined at the Finnish 
Institute of Occupational Health. The CT scans were scored using the 
Zinreich methodology (Kennedy et al. 2005). This is a modification of the 
Lund-Mackay scoring system, originally developed to score CT changes 
in chronic rhinosinusitis (Meltzer et al. 2006). Sinus opacification (mu-
cosal swelling and/or fluid) was scored from frontal, maxillary, anterior 
and posterior ethmoid and sphenoid sinuses both sides. Opacification 
of each sinus was scored on a six-point scale, 0 was scored for 0%, 1 for 
1%–25%, 2 for 26–50%, 3 for 51–75% and 4 for 76–99% and 5 for 
100% opacification, resulting in a maximum sum score of 50. Sinonasal 
obstructions of the frontal recess, middle meatus, infundibulum and 
sphenoethmoid recess were scored from both sides independently. No 
obstruction was scored as 0, partial or suspected obstruction was scored 
as 0.5 and total or definitive obstruction as 1. The maximum sum score 
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was 8. Additional natural or man-made ostia were also taken into account 
in scoring. The radiologists who scored the CT images were blinded 
with the patient information. A subset of images were scored by two 
radiologists (T. Vehmas and M. Varpula) in order to assess the intra and 
inter-reader consistency.
4.4  collection and preparation of biological  
 samples
4.4.1  nasal biopsies (i, ii, iii) 
Nasal biopsies were taken from the anterior superior part of the inferior 
conchae. For histological analysis they were fixed in 10% buffered formalin 
and embedded in paraffin. The samples taken for the polymerase chain reac-
tion (PCR) analysis were immediately quickly-frozen and kept in -70ºC.
4.4.2  induced sputum (iv)
The sputum was induced by inhaling hypertonic saline according to the 
current ERS Task Force guidelines (Djukanovic et al. 2002). PEF was 
measured before and after the procedure and bronchodilating medication 
was administered before sputum induction. The entire expectorant was 
processed. The sample was immediately processed. Prior to further pro-
cessing, a smear sample was obtained for cell analysis. DTT (Sputolysin 
reagent, KGaA /Calbiochem, Darmstadt, Germany) and water was added 
to the samples and they were incubated for 45 min, pre-filtered through 
nylon cloth and centrifuged (500g x) to remove cells. The liquid phase 
was filtered through 0.45 µm (Millex-hv PVDF, Millipore) and frozen 
to -80ºC. Protein concentration approximations were calculated from 
the protein gel band intensities by comparing the intensities (Image 
Quant 1D TL 7.0 software, GE Healthcare, Uppsala, Sweden) to known 
amounts of molecular weight markers. Sputum samples were concen-
trated five-fold with in ultracentrifugal concentrator tubes (VivaSpin 4, 
5000 MWCO PES, Sartorius Stedim Biotech, Goettingen, Germany). 
For proteomic analysis, 100 µg of each concentrated sample was used, 
and for Western blot analysis 3 µg of the untreated sample was used.
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4.4.3  nasal lavage fluid (iv)
The nasal lavage fluid sample was obtained by introducing a catheter 
into the anterior part of the nose with the neck flexed forward, and with 
the fingers pressing from outside, sealing the nostril. A total of 7.5 ml 
of physiologic solution was instilled into the nose with a syringe, and 
the procedure was repeated twice with the same liquid. The lavation was 
performed on both nostrils and the samples were combined. Immediately 
after sampling, the fluid was centrifuged at 500g x to separate cells from 
the liquid phase. After this, the supernatant was centrifuged again at 
4000g x and filtered through a 0.45 µm membrane (Millex-hv PVDF, 
Merk Millipore, County Cork, Ireland). Samples were frozen to -70ºC. 
Protein concentrations were measured with RC DC™ Protein Assay 
(BioRad, Hercules, CA, US). For the proteomic analysis, each sample 
was concentrated to 250 µl with ultrafiltration (Amicon Ultra-15 5000 
MWCO, Merk Millipore, County Cork, Ireland). Untreated samples 
were used for Western Blot, whereas ELISA analysis samples were concen-
trated by five-fold in SpeedVac (Thermo Scientific, Waltham, MA, US).
4.5  Assessment of inflammatory cells 
Nasal biopsies (Studies I, II, III) were cut in 2.5 µm thick sections, which 
were stained with hematoxylin and eosin. The samples were examined 
under light microscopy (Leica DM LB, Wetzlar, Germany). The numbers 
of eosinophils and neutrophils were counted in three high-power fields 
at x 400 magnification. 
Induced sputum cells (Study IV) were analysed from the smear sam-
ple obtained from the untreated sputum. The sample was stained with 
Tryptan blue and the total cell count and cell viability was assessed using 
hemocytometer. The cytospin preparation was made and the slides were 
stained with May-Grunwald-Giemsa stain. Thereafter, a differential cell 
count of 200 non-squamous cells was performed. The criteria for good 
quality sample was <60 squamous cells/ 200 non-squamous cells. 
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4.6  Real-time PcR analysis (i, ii, iii)
Real-time PCR was used to measure mRNA levels of cytokines in the 
nasal biopsy samples. Total cellular RNA was extracted using Trisure Re-
agent (Bioline, London, UK) according to the manufacturer’s protocol. 
The RNA content was measured by NanoDrop ND-1000 Spectropho-
tometer (NanoDrop Technologies Inc., Wilmington, DE). Extracted 
RNA was used as a template for complementary DNA (cDNA) synthesis. 
cDNA was synthesized from 0.5 µg of total RNA in a 25 µl reaction 
mixture using the High Capacity cDNA Reverse Transcription kit (Ap-
plied Biosystems, Carlsbad, CA, US). The quantitative Real Time-PCR 
was performed in a 96-well optical reaction plate in ABI PRISM 7500 
Fast Sequence Detector (Applied Biosystems, Carlsbad, CA, US) using 
predeveloped primers and probes from Applied Biosystems. The gene 
expression between samples was normalised with endogenous ribosomal 
18S. The cycle threshold value (CT) of a sample was determined accord-
ing to manufacturer’s instructions (Applied Biosystems, Carlsbad, CA, 
US). The results were calculated with 2−ΔΔCT method (Applied Biosys-
tems, Carlsbad, CA, US) using SDS 1.4 Software. We assessed mRNA 
expressions of the following cytokines in both study populations: IL-4, 
IL-5, IL-13, IL-17 and IFN-γ. In Study population A the expressions 
of TNF-α, IL-22, IL-6 and IL-10 were also detected.
4.7  microRnA assay (i, ii)
miRNA quantification was carried out as described by the manufacturer 
(Applied Biosystems, Carlsbad, CA, US) using TaqMan real-time PCR. 
Altogether 4 ng of total RNA containing the small RNA fraction was 
reverse transcribed by using the TaqMan MicroRNA Reverse Transcrip-
tion Kit and the miRNA-specific stem-loop primers (Applied Biosystems 
CA, US). The reverse transcription product (1.0 µl) was introduced into 
the 15-μl PCR reaction mixtures. Reaction mixtures were incubated in 
96-well plates on the ABI 7500Fast thermocycler (Applied Biosystems, 
Carlsbad, CA, US). Target gene expression was normalized between 
different samples based on RNU48 small nuclear RNA expression val-
ues. The results were calculated with the 2−ΔΔCT method with SDS 1.4 
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Software (Applied Biosystems, Carlsbad, CA, US). The expressions of 
the following miRNAs were assessed in both study populations: miR-7, 
miR-143, miR-187, miR-224, miR-498, miR-767-5p, miR-874 and 
miR-886-3p, let-7e, miR-18a miR-126, miR-146a, miR-155, miR-205, 
miR-210, miR-233 and miR-326. In addition, the following miRNAs 
were studied in Study population A: miR-17, miR-19a, miR-19-b1, 
miR-20a, miR-21, miR-26, miR-101, miR-125b, miR-132, miR-133, 
miR-142-3p, miR-146b, miR-147, miR-148b, miR-150, miR-152, 
miR-181a and miR-203.
4.8  2D-Dige (iv)
Before two-dimensional (2D) differential gel electrophoresis (DIGE) 
labelling, contaminants such as salts, detergents and lipids were removed 
from the sputum samples using ReadyPrep 2-D Cleanup kit (Bio-Rad 
Laboratories, Hercules, CA) according to the manufacturer’s instructions. 
A total of 50 μg of protein from each sample was used for analysis. The 
labelling was also performed according to the manufacturer’s instructions 
(Amersham CyDye DIGE flours (minimal dye) for Ettan DIGE (GE 
Healthcare Biosciences, Pittsburgh, PA, US). The protein samples were 
suspended in 2 µg/µL DIGE labelling buffer and they were labelled ran-
domly with fluorescence dyes Cy3 and Cy5. A pooled internal standard, 
containing equal amounts of protein from all samples was labelled with 
Cy2 in order to decrease technical variation and to align spots during 
analysis. The labelled samples were absorbed into 18 cm long pH interval 
3–10 non-linear Immobiline DryStrips (GE Healthcare, Biosciences, 
Pittsburgh, PA, US). The strips were rehydrated for six hours with a 
rehydration buffer, after which the proteins were absorbed on the strips 
with the cup loading method. Proteins were separated vertically using 
isoelectric focusing with ETTAN IPGphor II (Amersham Biosciences, 
Uppsala, Sweden). Isoelectric focusing started with direct current from 
150 volts and raising volts in five steps within 19 hours to 8000 volts. 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE) was performed to separate proteins by their size; the runs were 
performed with Ettan DALT (GE Healthcare Biosciences, Pittsburgh, 
PA, US) using 15 Watts per gel. After electrophoresis, the fluorescence of 
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the protein gels was scanned with the Ettan DIGE imager (GE Health-
care Biosciences, Pittsburgh, PA, US) with a resolution of 40 μm using 
specific wavelengths for each of the three dyes. DeCyder 2-D Differential 
Analysis Software v.7.0 (GE Healthcare Biosciences, Pittsburgh, PA, US) 
was used for spot detection, quantification and the search for abundance 
differences. Protein spots with ≥ |1.5| fold change in abundance and 
with Student’s t-test p-value ≤ 0.05 between different study groups were 
chosen for mass spectrometry identification.
4.9  tandem mass Spectrometry (iv)
The gels were silver stained and the significantly up-or down-regulated 
protein spots were cut from the gel, reduced with DTT, and alkylated 
with iodoacetamide to prepare them for in-gel digestion with trypsin 
for 16 hours. The formed peptides were extracted from the gel pieces, 
dried in a vacuum centrifuge, and dissolved in 2% formic acid. Each 
peptide mixture was analysed with automated nanoflow capillary liq-
uid chromatography (LC) – tandem mass spectrometry (MS) using 
CapLC system (Waters, Milford, MS, US) coupled to an electronspray 
ionization quadrupole time-of-flight mass spectrometer (Waters). The 
obtained mass fragment spectra were analysed using Mascot v.2.1 Soft-
ware (Matrix Science Ltd., London, UK) and compared against human 
entries in the NCBInr database. Hierarchical clustering and principal 
component analysis of the identified proteins were performed with 
DeCyder Extended Data Analysis software (GE Healthcare Biosciences, 
Pittsburgh, PA, US).
4.10  immunological validation (iv)
4.10.1 Western blot
Sputum or nasal lavage fluid samples were loaded into precast 26-well 
12% Criterion TGX gels (Bio-Rad laboratories, Hercules, CA, US) and 
separated at 100V for 5 minutes and 200V for 60 minutes in buffer. A 
pool of all test samples was used as an internal standard on each gel to 
provide a reference for the normalisation of the results. Proteins were 
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transferred onto polyvinylidene difluoride membranes (Millipore, Billeri-
ca, MA, US) using the Criterion Blotter (Bio-Rad laboratories, Hercules, 
CA, US) at 300 mA for 2 hours in a transfer buffer. Anti-FABP5 (Abcam 
#ab84028) primary antibody dilution was 1:800. Immonoblot staining 
was performed with anti-rabbit peroxidase-conjugated immunoglobulin 
(1:1000) (Dako Cytomaton, Glostrup, Denmark) and chemiluminescent 
HRP-substrate ECL detection reagent (Perkin Elmer, Waltham, MA, 
US). They were visualised using Image Quant LAS 4000 mini quantita-
tive imager (GE Healthcare Biosciences, Pittsburgh, PA, US) and the 
intensities of the protein band were analysed with ImageQuant TL (GE 
Healthcare Biosciences, Pittsburgh, PA, US).
4.10.2 eliSA
Commercial ELISA immunoassays (Invitrogen, Camarillo, CA, US) were 
used to measure protein levels of VEGF and CysLT in the nasal lavage 
fluid. The CysLT kit measured all three CysLT metabolites: TLC4, LTD4 
and LTE4. The analysis was performed according to the manufacturer’s 
instructions with five-fold concentrated nasal lavage fluid.
4.11  Statistical methods
Data consisted of both continuous and categorical values. We ex-
pressed continuous variables and expressed them as means ± standard 
deviation (SD), or medians and quartiles (Q) 1–3. Categorical values 
were expressed as percentages. When exploring differences between 
the groups we applied Chi-square test for categorical variables. For the 
continuous normally distributed variables we used ANOVA and for the 
non-normally distributed variables Kruskal-Wallis test. Student’s t-test 
or the Mann-Whitney U-test were used as post-hoc tests for continuous 
variables and Bonferroni correction was used for multiple comparisons. 
We computed Pearson or Spearman’s correlation between the continu-
ous variables and analysed the intra- and inter-reader agreements by 
using the single measures intraclass correlation (weighted kappa). The 
effects of the confounding factors were studied by using multinomial 
logistic regression model and general linear model. A p-value of <0.05 
was considered statistically significant. 
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The analyses were carried out with IBM SPSS Statistics for Windows, 
Version 20.0 (IBM Corp, Armonk, NY, US) software and GraphPad 
Prism 5 software (GraphPad, San Diego, CA, US). For the Gene On-
tology annotations and hierarchical clustering analyses of the proteins 
(Study IV) we used DeCyder 2-D Differential Analysis Software v.7.0, 
(GE Healthcare Biosciences, Pittsburgh, PA, US).
4.12 ethics
All the subjects signed an informed consent document. Studies I, III 
and IV were approved by Turku University and the Turku University 
Central Hospital Ethics Committee (approval number 19/180/2008). 
Study II was approved by the Ethics Committee of the Department of 
Medicine of Helsinki University Central Hospital (approval number 
284/13/03/00/08). 
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5  ReSultS
5.1  clinical characteristics of the study   
 subjects
5.1.1  Study population A (i, iii, iv)
The main characteristics of Study population A are shown in Table 2. We 
detected no significant differences between the study groups (control, al-
lergic rhinitis, allergic rhinitis and asthma, nonallergic rhinitis) in terms of 
age, smoking or BMI. Gender distribution was not equal, there were more 
women than men in all groups, and the biggest proportion of women was 
in the nonallergic rhinitis group. Based on the SPT results, most of the 
subjects in the allergic rhinitis and asthma group were sensitized to mul-
tiple allergens, both to perennial and seasonal allergens. After the subjects 
with current respiratory infection symptoms were excluded (Study I) we 
detected a significant difference in the total IgE level between the groups 
(p<0.01), the level of IgE was higher in allergic rhinitis (mean 213.6, SD 
416.5) and allergic rhinitis and asthma (mean 195.9, SD 220.3) groups 
compared to nonallergic rhinitis (mean 43.9, SD 69.6) and control groups 
(mean 32.1, SD 37.2). We detected no significant differences between the 
groups in FVC% (p=0.09), FEV1% (p=0.52) or FEV1/FVC (p=0.11). 
Instead, we found significant differences in the VAS scores in rhinorrhoea, 
nasal congestion and itchiness between the groups. The highest score for 
rhinorrhoea was found in the allergic rhinitis and asthma group (median 
24.0 mm Q1–Q3 9.3–38) and in the nonallergic rhinitis group (median 
24.0 mm, Q1–Q3 6.8–50). The highest nasal congestion score was detected 
in the nonallergic rhinitis group (median 18.5 mm, Q1–Q3 7.8–60) and 
the score for nasal itchiness was most elevated in the allergic rhinitis group 
(median 16.0 mm, Q1–Q3 3.8–50).
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Table 2. Main characteristics of Study population A and B.
Study population A
(n=179)
Study population B 
(n=157)
Men, n (%) 63 (35) 157 (100)
Age, year, mean (SD) 33.1 (1.5) 41.2 (1.9)
Current smokers, n (%) 14 (7.8) 44 (28)
BMI, kg/m2 (SD) 23.9 (3.8) 27.5 (4.9)
SD= standard deviation, BMI=body mass index
5.1.2  Study population b (ii)
In Table 2, the essential characteristics of study population are shown. 
We did not detect statistically significant differences in smoking or BMI 
between the study groups. Four subjects with respiratory infection, one 
subject with diaphragm relaxation and one subject on whom SPTs were 
not performed were excluded from the analysis. The asthma group was 
divided into two subgroups, persistent (n=63) and nonpersistent (n=54) 
based on the asthma severity. Allergic rhinitis was detected in 79% of the 
subjects of the nonpersistent asthma group and in 85% of the subjects 
in the persistent asthma group. Altogether 84% of the subjects in the 
nonpersistent asthma group and 89% of the subjects in persistent asthma 
group were sensitized to common environmental allergens, most of them 
both to seasonal and perennial allergens. In the control group, 24% were 
sensitized to environmental allergens, but they did not report respiratory 
symptoms related to these allergens. Total IgE and blood eosinophils 
were significantly increased in both nonpersistent and persistent asthma 
compared to controls (p<0.01). The persistent asthma group had signifi-
cantly lower lung function parameters (FVC% of predicted, FEV1% of 
predicted or FEV1/FVC) compared to the controls and the nonpersistent 
asthma group (p<0.01). In Table 3, the VAS scores of nasal symptoms 
are presented. A significant difference between the groups was detected 
in rhinorrhoea, nasal congestion as well as in nasal itching.
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Table 3. Visual analogue scale (VAS) rhinitis scores of Study 
population B.
Total 
(n=156)
Control 
(n=34)
Non
persistent
asthma
(n=65)
Persistent 
asthma 
(n=57)
P-value
VAS score 
rhinorrhoea, 
mm, mean (SD) 
27.3
(24.6)
20.9 
(18.7)
23.9 
(22.6)
35.2
(28.1)
0.027
VAS score nasal 
congestion, 
mm, mean (SD) 
31.1
(27.1)
19.0
(21.5)
28.2 
(25.8)
41.9 
(27.9)
<0.01
VAS score nasal 
itchiness,  
mm, mean (SD) 
19.1
(21.7)
10.7 
(16.5)
18.8 
(19.8)
24.4
 (24.9)
<0.01
5.2  nasal cytokine and microRnA    
 expressions (i, ii)
5.2.1  Study i
When mRNA expressions of cytokines in nasal biopsies were compared 
between the four study groups (control, allergic rhinitis, allergic rhinitis 
combined with asthma, nonallergic rhinitis), we detected significant dif-
ferences in the levels of Th2 cytokines. When compared to controls, we 
detected up-regulation of IL-13 mRNA in the allergic rhinitis (p<0.05) 
and in the allergic rhinitis and asthma group (p<0.05). Similarly, when 
compared to the nonallergic rhinitis group, IL-13 mRNA was up-regu-
lated in the allergic rhinitis group (p<0.05) and the allergic rhinitis and 
asthma groups (p<0.05). In addition, we detected up-regulation of IL-4 
mRNA in the allergic rhinitis group compared to the control (p<0.05) 
and nonallergic rhinitis group (p<0.05) and an up-regulation of IL-5 
mRNA in the allergic rhinitis and asthma group compared to the con-
trols (p<0.05). A slight increase in nasal nitric oxide level in the allergic 
rhinitis and allergic rhinitis and asthma groups as well as in the number 
of eosinophils in nasal biopsies in the allergic rhinitis and asthma group 
was also detected, but the differences were not statistically significant.
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We also detected an upward trend in the levels of miR-205, miR-155 
and miR-498 in the allergic rhinitis group and a downward trend in 
let-7e in the allergic rhinitis and asthma groups. When subgroups of sub-
jects with non-current rhinitis symptoms (n=87) and current symptoms 
(n=38) were compared between the groups, we found increased levels of 
miR-205 (p<0.01), miR-155 (p<0.01) and miR-498 (p<0.05) in the cur-
rently symptomatic allergic rhinitis group compared to the controls. These 
miRNAs were also significantly up-regulated in the allergic rhinitis group 
compared to the nonallergic rhinitis group. Instead, let-7e was significantly 
down-regulated in the allergic rhinitis and asthma group without current 
rhinitis symptoms compared to the controls (p<0.05) and nonallergic 
rhinitis group (p<0.05). We also detected that let-7e was down-regulated 
(p<0.05) whereas miR-205 (p<0.05) and mR-155 (p<0.05) up-regulated 
in subjects with positive SPTs compared to those with negative SPTs.
5.2.2  Study ii
In Study population B we detected an increased level of exhaled nitric 
oxide and a decreased level of IFN-γ mRNA in nasal biopsy in both 
asthma groups compared to the controls. No significant differences were 
detected in the nasal nitric oxide level, the eosinophil count or the Th2 
cytokine mRNA levels in the nasal mucosa.
Altogether ten miRNAs were differentially expressed in the nasal 
mucosa of the asthma patients compared to the controls (all p<0.05). 
The levels of miR-18a, miR-126, let 7e, miR-155 and miR-224 were 
down-regulated, and miR-498, miR-187, miR-874, miR-143 and miR-
886-3 up-regulated in the asthmatics. There was no significant differences 
between the non-persistent and persistent asthma groups in the expres-
sions of these miRNAs. However, there was a tendency for more distinct 
up-regulation in the persistent asthma group whereas a tendency for more 
distinct down-regulation in the non-persistent asthma group was seen.
When a subgroup of asthmatics with concomitant allergic rhinitis 
were compared with the controls, a down-regulation of three miRNAs: 
miR-18a, miR-126, miR-155 and an up-regulation of two miRNAs: 
miR-498 and miR-187 was detected. miR-18a, miR-126, miR-155 
and miR-498 were also differentially expressed in asthmatics without 
concomitant allergic rhinitis compared to the controls. We also found a 
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positive correlation between miR-155 and exhaled nitric oxide (r=0.32, 
p<0.01), miR-155 and nasal nitric oxide (r=0.36, p<0.01) and miR-155 
and IL-13 mRNA (r=0.38, p<0.01) miR-155 and IgE (r=0.21, p=0.024), 
and an inverse correlation between miR-489 and IFN-γ levels (r=-0.39, 
p<0.01) in asthmatics.
5.3  nasal nitric oxide and nasal  
 ct findings (iii)
In Study population A, we examined associations between nasal nitric 
oxide levels and nasal CT scores of sinus opacification and obstruction. 
A total of 175 subjects were included in the analysis and divided into 
three groups: controls (n=42), subjects with allergic rhinitis (including 
subjects with allergic rhinitis with and without asthma) (n=89) and sub-
jects with nonallergic rhinitis (n=44). One subject with asthma but no 
rhinitis and three subjects who had used inhaled steroids in the previous 
two weeks were excluded from the analysis. 
Based on Zinreich CT scoring, partial or total obstruction of the 
ostia was detected in 15.3% of the subjects in the frontal recesses, 6.3% 
in the middle meatus, 22.2% in the infundibula and in 11.4% in the 
sphenoethmoid recess. We did not detect statistically significant dif-
ferences in the obstruction score (p=0.60) or in the opacification score 
(p=0.25) between the study groups. A significant correlation between 
the opacification and obstruction scores (r= 0.60, p< 0.01) was detected. 
The level of nasal nitric oxide was increased in the allergic rhinitis group 
(p=0.035) compared to the control group, and it was negatively associated 
with sinus obstruction (p<0.01). When we blotted nasal nitric oxide on 
the total obstruction score, we found that nasal nitric oxide started to 
decrease in the allergic rhinitis group when the total obstruction score 
exceeded 2 (Figure 3). In the control group and nonallergic rhinitis group 
this phenomenon was not as distinct.
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Figure 3. Nasal nitric oxide (nNO) plotted on total obstruction score sepa-
rately in subjects with allergic rhinitis (AR) and in subjects with nonallergic 
rhinitis and controls (NAR+ Control).
When allergic rhinitis patients without significant obstruction in ostia, 
i.e. subjects with obstruction score <2 (n=79), were analysed, we found 
a significant correlation between nasal nitric oxide and exhaled nitric 
oxide (r=0.28, p< 0.05), nasal nitric oxide and opacification score (r=0.25, 
p< 0.05), and nasal nitric oxide and nasal eosinophils (r=0.29, p< 0.05). 
However, the correlation between nasal nitric oxide and IL-13 mRNA 
was not statistically significant (r=-0.05, p>0.05).
5.4 Sputum proteomics (iv)
Altogether 172 subjects in Study population A were included in Study IV; 
seven subjects with nonallergic asthma were excluded. Induced sputum 
samples of 21 subjects (4 from the allergic rhinitis group, 6 from the 
allergic rhinitis and asthma group, 6 from the nonallergic rhinitis group 
and 5 from the control group) were selected for the proteomic analysis. 
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No statistically significant differences in the sputum protein concentra-
tion were detected between the groups. The protein concentrations of 
the nasal lavage fluid samples varied between 0.03–0.19 mg/ml, and no 
statistically significant differences were detected between the groups. 
The proteomic analysis revealed 80 differentially expressed (at least 
1.5 fold change in expression and p<0.05 in the student’s t-test) proteins 
in sputum and 63 proteins in nasal lavage fluid. Altogether 31 different 
sputum proteins were identified; these were also identified in the nasal 
lavage fluid. The hierarchical clustering showed differences in expression 
patterns, especially between the asthma with concomitant allergic rhi-
nitis group and the control group as well as between the allergic rhinitis 
group and the control group. The Gene Ontology (GO) classification 
of the biological processes associated with the proteins found are shown 
in Figure 4. Response to stimulus was the most enriched among the 
identifications.
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platelet	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Figure 4. The gene ontology (GO) on biological processes connected to the 
identified induced sputum proteins.
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In 2D-DIGE, we detected significant differences between the groups 
in the protein abundances in several proteins including FABP5, in 
Chinatinase-3-like-protein 2 (CH3L2), Carbonic anhydrase 6 (CAH6) 
Cysteine-rich secretory protein 3 (CRISP3). These proteins were vali-
dated in the whole study population using immunoblotting. The level of 
FABP5 was significantly increased in the asthmatics both in the sputum 
and in the nasal lavage fluid compared to the controls, no statistically 
significant differences between the study groups were detected in other 
assessed proteins. The level of FABP5 significantly positively correlated 
with both VEGF and CysLT levels in nasal lavage fluid.
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6.1  Study populations and clinical findings
Study population A (studies I, III, IV) was a young adult population, 
consisting of men and women aged 31 to 38 years. The study group was 
randomly selected on the basis of the answers to the follow-up postal 
questionnaire. The gender distribution was concordant with that of the 
study of Molgaard and colleagues (2007), which reported that nonallergic 
rhinitis was twice as common among women than among men, whereas 
the gender distribution is more equal in allergic rhinitis. No significant 
differences were detected between the study groups in smoking habits, 
BMI or age.
The mean VAS scores of nasal symptoms in the four groups were low, 
reflecting mild rhinitis severity. The symptom scores of rhinorrhoea and 
nasal congestion were similar in the allergic rhinitis and nonallergic rhi-
nitis groups, whereas the nasal itching score was lower in the nonallergic 
rhinitis group. Our findings are similar to the earlier reports (Molgaard 
et al. 2007). The asthma group had normal mean spirometric values 
(FVC%, FEV1% and FEV1/FVC) and exhaled nitric oxide level. Most 
of the asthmatics did not take regular asthma medication. These results 
indicate that the asthma severity in the asthma group was mainly low.
Study population B (study II) comprised middle-aged men who had 
been in military service approximately 20 years ago and thus the results 
cannot be generalised in women and other age groups. The study popula-
tion is rather homogenous in terms of age, nationality, sex and smoking 
habits diminishing the confounding factors. The asthma group mainly 
represents the early onset allergic phenotype (Wenzel 2012). However, 
there is a subgroup of asthmatics without concomitant allergic rhinitis 
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(23 subjects, 18%) and without allergic sensitization (15 subjects, 13%) 
in the population. We can presume that we studied mainly chronic 
changes in the nasal mucosa instead of acute allergic reactions, because 
the subjects were examined outside pollen season and the VAS scores of 
nasal symptoms were low. The symptoms of nasal congestion and itching 
were increased in the asthma and allergic rhinitis group and also in the 
asthmatics without concomitant allergic rhinitis. Our results are in line 
with a previous study showing that asthma is associated with rhinitis also 
in non-atopic subjects (Leynaert et al. 2004). The VAS scores of nasal 
symptoms were significantly increased in subjects with persistent asthma 
symptoms compared to those with nonpersistent symptoms. These find-
ings are concordant with studies showing an association between asthma 
and rhinitis severity and increased severity of asthma and an increase in 
nasal symptoms (Magnan et al. 2008; Eriksson et al. 2011). However, 
some studies have not found a clear association between asthma and 
rhinitis severity (de Marco et al. 2006; Antonicelli et al. 2013).
Current asthma severity was assessed on the basis of symptoms, lung 
function and treatment using the GINA guidelines 2002 version, as in 
previous studies (de Marco et al. 2006), and is described in more detail 
in the former study of Lindström and colleagues (2012). Approximately 
half of the subjects had asthma remission or intermittent asthma and the 
other half mild, moderate or severe persistent asthma. The distribution 
of asthma severity was in line with a previous population-based report 
on the same age group (de Marco et al. 2006).
6.2  nasal microRnAs (i, ii)
We studied the miRNA expressions in nasal biopsies of the two study 
populations (A and B). The microarray analysis was performed similarly 
in both studies. Based on knowledge at the time of the analysis, we 
selected for the analysis of 28 miRNAs in Study I and 14 miRNAs in 
Study II, linked to allergic rhinitis and asthma, allergy, inflammation or 
immunological responses. Information regarding miRNAs has increased 
rapidly in recent years, and some miRNAs currently linked to allergic 
inflammation were not included in the analysis. 
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We found some differentially expressed miRNAs in the nasal mucosa 
of the allergic rhinitis and asthma patients, but no changes in the miRNA 
expression in the mucosa of the nonallergic rhinitis patients compared 
to the controls. As a whole, the differences in the miRNA expressions 
were rather modest in Study population A (Study I), with mild asthma 
and rhinitis. In this population, statistically significant differences in 
four miRNA expressions were found in the subgroups of subjects with 
currently symptomatic and non-symptomatic allergic rhinitis. We also 
found increased levels of Th2 cytokines in subjects with allergic rhinitis 
and asthma. In nonallergic rhinitis, other than inflammatory mechanisms 
are thought to be essential. Thus, it is not surprising that the expressions 
of assessed miRNAs of the nonallergic rhinitis group and the control 
did not differ.
In Study population B (Study II) 11 differentially expressed miRNAs 
were detected in asthmatic subjects. We also found an increase in blood 
eosinophil count and decreased level of IFN-γ in the nasal mucosa. 
However, we did not find an increase in the Th2-type cytokines. The 
differences between the findings of these studies may reflect the longer 
duration of asthma and rhinitis and more severe asthma in population B 
(study II) and on the other hand more symptomatic subgroup of allergic 
rhinitis patients in the population A (Study I).
We studied biopsy samples of nasal mucosa including several cell 
types. Similarly, Williams and colleagues (2009) examined bronchial 
biopsies of mild asthmatics and healthy controls and found no dif-
ferences in the miRNA expressions between these groups or after the 
inhaled steroid treatment of asthmatics. Whereas, Solberg and colleagues 
(2012) investigated miRNA expressions of bronchial epithelial cells 
obtained from steroid naïve asthmatics and healthy controls and found 
markedly abnormal pattern of miRNAs in the asthmatics, altogether 
217 differentially expressed miRNAs were detected. In addition, Jardim 
and colleagues (2012) found 66 differentially expressed miRNAs in the 
cultured epithelial cells of asthmatics when compared to controls. The 
differences in the numbers of differentially detected miRNAs may reflect 
the differences in the studied sample types. 
Shaoquing and colleagues (2011) used a microarray chip of 421 
miRNAs to analyse nasal biopsies of allergic rhinitis patients. They 
detected nine miRNAs with more than a two-fold change in expression 
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in the allergic rhinitis patients. We included eight of these miRNAs in 
the analysis in both of the studies. We found difference in the expression 
in only one of these miRNAs. Interestingly, miR-498 was up-regulated 
in the allergic rhinitis group, whereas in the former study it was down-
regulated. In study II, six of these miRNAs were differentially expressed 
in the asthmatics. Similarly, five of the miRNAs up-regulated in our 
study, were down-regulated in the study of Shaoquing and colleagues 
(2011). These differences may be explained by the complex functions 
and networks of miRNAs as well as differences in the study populations. 
The population of Shaoquing and colleagues (2011) comprised subjects 
undergoing surgery for nasal obstruction. We may assume that the nasal 
disease in that population was more severe or complicated than in our 
populations. 
We detected three miRNAs differentially expressed in the both stud-
ies: miR-155, miR-498 and let 7e. In study I, miR-155 was up-regulated 
in the symptomatic allergic rhinitis patients and in the atopic subjects 
compared to non-atopic ones. In study II, it was down-regulated in 
asthmatics with and without allergic rhinitis and a weak positive correla-
tion between miR-155 and exhaled and nasal nitric oxide was detected. 
MiR-155 has been found to play an important role in the Th2 inflam-
mation by modifying macrophage reaction to IL-13 (Martinez-Nunez 
et al. 2011) and in mouse models miR-155 deficiency has been shown 
to result in decreased Th2 cytokine levels and eosinophilic inflammation 
(Malmhall et al. 2014). Let 7e was down-regulated in asthmatic subjects 
in both studies and also in atopic subjects compared to non-atopic in 
study I. It belongs to a let-7 family, which has been demonstrated to 
influence the expression of IL-13 in lung epithelial cell line and intra-
nasal administration of let-7 has been shown to reduce IL-13 level and 
hyperresponsiveness and lead to resolution of allergic inflammation in 
the mouse model (Kumar et al. 2011). However, the inhibitor of let-7 
inhibited the allergic cytokine production and disease phenotype in 
the mouse model (Polikepahad et al. 2010). mir-498 was up-regulated 
in symptomatic allergic rhinitis patients (study I) and in subjects with 
allergic rhinitis and asthma, and also in asthmatics without allergic 
rhinitis (Study II). It also inversely correlated with the IFN-γ level in 
asthmatics. miR-498 was also down-regulated in the previous study 
on allergic rhinitis patients (Shaoqing et al. 2011) but the function of 
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miR-498 in allergic inflammation is not known. It is highly expressed 
in some cancers (Schepeler et al. 2008) and recently depletion of T-cell 
intracellular antigen has been shown to cause up-regulation of miR-498 
(Sanchez-Jimenez et al. 2013).
We found some differences between the miRNA expressions in the 
nasal mucosa of subjects with asthma and allergic rhinitis and those of 
the controls. No differences in nasal eosinophil count was found between 
those groups. These findings may indicate, that panel of miRNAs might 
be more sensitive in assessing of allergic inflammation than traditional 
markers. Moreover, differences in the miRNA expressions in nasal mu-
cosa were detected in asthmatics with and without concomitant allergic 
rhinitis, suggesting that nasal mucosa could be as useful as a surrogate 
of bronchial epithelium in assessing inflammation in asthma.
6.3  nasal nitric oxide in rhinitis (iii)
We found a slight increase in the nasal nitric oxide level in allergic rhi-
nitis. This finding is in line with early studies by Kahritonow and col-
leagues and Arnial and colleagues (Arnal et al. 1997; Kharitonov et al. 
1997). In contrast, other studies have found no significant increases in 
nasal nitric oxide levels in allergic rhinitis (Henriksen et al. 1999; Palm 
et al. 2003). The discrepancy between the studies may partly be due to 
obstruction of the sinus ostia caused by mucosal swelling (Maniscalco 
2010). We used the breath-holding method to collect nasal nitric oxide. 
Nitric oxide collected with this method has been proposed to reflect 
the nitric oxide level in nasal mucosa, whereas the humming method 
releases nitric oxide from sinuses (Maniscalco et al. 2004). By using the 
humming method we could have detected bigger differences between 
subjects with and without ostial obstruction. The level of nasal nitric 
oxide correlated with the level of exhaled nitric oxide as shown in the 
previous studies (Williamson et al. 2010).
We used Zinreich classification to score opacification of the sinuses 
and obstruction of the sinus ostia in nasal CT. It is a more sensitive scor-
ing method to score sinus opacification than the Lund-Mackay score, 
which has been widely used to score changes nasal CT changes (Meltzer 
et al. 2006). The levels of opacification and obstruction were low in all 
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the groups. We detected no differences between the study groups, which 
is in line with the previous studies and supports the view that limited 
mucosal changes in CT scans are not indicative for allergy (Ono et al. 
2011; Shusterman et al. 2012).
When we studied a subgroup of allergic rhinitis patients without 
marked sinus ostia obstruction, we detected a positive correlation between 
the nasal nitric oxide level and sinus opacification. In the previous studies 
using the Lund-Mackay scoring system in allergic rhinitis and healthy 
controls a negative correlation has been found (Shusterman et al. 2012). 
This discrepancy may be due to the more sensitive scoring system in our 
study and an interaction between opacification and obstruction in the 
previous studies. We also found a significant positive correlation with the 
nasal nitric oxide level and the nasal eosinophil count in these subjects. 
This finding is in line with studies showing associations between sputum 
eosinophils and exhaled nitric oxide (Berry et al. 2005b) and supports the 
view that nasal nitric oxide reflects eosinophilic inflammation in the nasal 
mucosa, but is affected by sinus ostia obstruction in allergic rhinitis. This 
reduces the feasibility of nasal nitric oxide in the assessment of airway 
inflammation and monitoring allergic rhinitis in clinical work. When a 
high level of nasal nitric oxide is detected in an allergic rhinitis patient, it 
might be taken as an indicator of allergic inflammation and suggest that 
distinct ostial obstruction is present. However, several factors including 
exercise, medication and respiratory viral or bacterial infections affect 
nasal and exhaled nitric oxide levels (ATS/ERS 2005). It is important to 
pay attention to respiratory infection symptoms before measuring nasal 
or exhaled nitric oxide.
6.4  Sputum proteomics (iv)
We assessed induced sputum proteome in a subgroup of 21 non-smoking 
subjects with allergic rhinitis, asthmatics with allergic rhinitis, nonallergic 
rhinitis and healthy controls. We identified 31 differentially expressed 
proteins, which were also found in nasal lavage fluid. This is in line with 
the findings of the previous study, in which eosinophilia in the nasal 
lavage fluid was found to be a good predictor of sputum eosinophilia 
(Amorim et al. 2010). The nasal lavage fluid method has some advantages 
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compared to the induced sputum. It is well tolerated and a sample can 
be obtained from almost all adults. Instead, the induced sputum sample 
cannot be obtained from at least 10‒20% of the subjects (Belda et al. 
2000; Spanevello et al. 2000; Matsuoka et al. 2008). Moreover, the nasal 
lavage fluid cells can be separated from the liquid phase without chemical 
treatment, whereas induced sputum treatment with DTT may harm the 
analysis of some mediators (Efthimiadis et al. 1997; Kelly et al. 2000). 
However, the validity and the reproducibility of techniques to detect 
fluid-phase markers in sputum or nasal lavage fluid are not assessed as 
well as in cell analysis, and considerable variability has been observed in 
some markers (Stockley et al. 2000; Boot et al. 2008).
In the sputum proteomic analysis, the abundance of FABP5 was 
increased in the asthmatic subjects when compared to the subjects with 
allergic rhinitis and those with nonallergic rhinitis. In the immunoblot 
validation in the whole study population, we found increased levels of 
FABP5 in both induced sputum and nasal lavage fluid in asthmatics. 
FABP5 belongs to the family of small cytosolic lipid-binding proteins, 
fatty acid binding proteins, which regulate glucose and lipid homeostasis 
and inflammation through their actions in adiposytes and immune cells 
(Makowski et al. 2005a; Yamamoto et al. 2008). It has been linked to 
Th17 and T-regulatory cell differentiation, inflammatory responses and 
oxidative damage (Makowski et al. 2005b; Rolph et al. 2006; Li et al. 
2009). We detected a positive correlation between VEGF and FABP5. 
VEGF is and epithelium derived cytokine associated with Th2 inflam-
mation and airway remodeling (Lee et al. 2004; Chetta et al. 2005). 
In addition, we detected a significant correlation between FABP5 and 
CysLTs, which has been shown to up-regulate VEGF production (Pou-
lin et al. 2011). Our findings suggest that FABP5 may participate in 
the regulation of airway inflammation and remodelling by CysLTs and 
VEGF mediated cell signalling cascades, and thus might be useful as a 
biomarker of allergic asthma phenotype in the future.
6.5  limitations of the studies
There are some limitations related to the study population. The popu-
lation comprised men and women aged around 30–50 years. Most of 
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the asthmatics represented the early onset allergic phenotype. Thus, the 
findings of this thesis cannot be generalized to other age groups or other 
asthma phenotypes. In Study population A, the subjects mainly had mild 
asthma and rhinitis and currently had mild symptoms. In Study popula-
tion B, the samples were taken outside the pollen season and the rhinitis 
symptoms of the subjects were mainly mild. We may have found more 
distinct differences in the biomarkers between the groups if the subjects 
we studied had had more severe diseases (i.e. patients from outpatient 
policlinics). Many of the subjects had earlier used inhaled or nasal steroid 
medications. Even though the medication was mainly withheld before 
the samples were taken, it may have had some effect on the results. We 
could have found bigger differences in evaluated markers between the 
groups if we had analysed samples of steroid naïve subjects. 
There are also some limitations in the sample techniques and analy-
sis. miRNAs were analysed from the biopsy samples, in which cellular 
heterogeneity may mask the differences in the miRNA expressions in the 
individual cell types. Based on current knowledge, analysis of the cultured 
epithelial cells of the study subjects and the use of a panel of multiple 
miRNAs might have revealed more differentially expressed miRNAs. 
However, these methods were not technically achievable at the time of 
the analysis. In Study III, more distinct differences may have been found 
between the nasal nitric oxide of the groups if the humming method 
had been used. Similarly in Study IV, the protein separation and mass 
spectrometry technique we used results in fewer protein identifications 
than more advanced techniques.
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The main findings and conclusions of the study: 
1. Some differences were detected between the miRNA expressions in 
the nasal biopsies of the subjects with symptomatic allergic rhinitis 
and the healthy controls as well as between the non-symptomatic 
subjects with allergic rhinitis and asthma the healthy controls. No 
differences were found between the subjects with nonallergic rhini-
tis and the healthy controls. The miRNA expressions were relatively 
similar in the subjects with allergic rhinitis without asthma and 
in those with concomitant asthma. As a whole, the differences in 
miRNA expression were rather modest.
2. Differences were detected between the miRNA expression in the 
nasal biopsies of subjects with long term asthma and allergic rhi-
nitis and those of the controls. Only suggestive differences in the 
miRNA expressions were found on the basis of asthma severity. 
Some changes in the miRNA expressions in the nasal biopsies 
were also found in the asthmatics without concomitant allergic 
rhinitis. Differences in miRNA expressions were also found in the 
nasal mucosa of the asthmatics, when differences in the eosinophil 
count could not be detected. This finding suggests that a panel of 
miRNAs might be a more sensitive marker of allergic inflammation 
than traditional markers. 
3. Nasal nitric oxide was slightly elevated in allergic rhinitis patients 
compared to healthy controls, and it associated with exhaled nitric 
oxide. Sinus ostial obstruction negatively correlated with the level 
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of nasal nitric oxide in subjects with allergic rhinitis. In subjects 
without marked ostial obstruction, we found a positive correlation 
of nasal nitric oxide with sinus opacification and with nasal eosino-
phil count. We did not, however, detect an association with nasal 
nitric oxide and Th2 type cytokine IL-13. The feasibility of nasal 
nitric oxide assessment in clinical practice is limited, because sinus 
ostial obstruction may effect nitric oxide level. Nevertheless, a high 
level of nasal nitric oxide in an allergic rhinitis patient indicates 
eosinophilic inflammation in the nasal cavity and the absence of 
marked sinus ostial obstruction.
4. Proteomic analysis of sputum and nasal lavage fluid identified the 
same proteins in both samples. We found an increased abundance 
of FABP5 in the induced sputum of allergic asthmatics. Elevated 
levels of FABP5 were detected in the immunoblot validation in 
both the sputum and nasal lavage fluid. The FABP5 level also cor-
related with VEGF and CysLT levels, indicating its potential role 
in inflammation and remodelling in asthma. These findings suggest 
that sputum proteome analysis is a useful tool when searching for 
potential candidate asthma biomarkers, and that nasal lavage fluid 
might be useful in assessing asthma markers. 
Our findings support the view of asthma and rhinitis as manifestations of 
one airway disease and that inflammation of the upper and lower airways 
in allergic rhinitis and asthma is similar. Biological samples are easier to 
obtain from upper than lower airways. Thus, markers obtained from the 
upper airways could be used in assessing lower airway inflammation in 
the future. Our results suggest that new sensitive biomarker panels for 
the clinical evaluation of allergic airway inflammation may be found by 
using miRNA analysis and proteomics.
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Airway inflammation in asthma and allergic rhinitis share common 
characteristics, and these conditions can be seen as manifestations 
of one disease. The aim was to investigate airway inflammation 
biomarkers in the light of this view.
We dected differences in microRNA expression in the nasal mucosa 
of asthma and allergic rhinitis patients when no significant 
differences in the inflammatory cells and cytokines were found. 
A biomarker was found in the sputum of the asthmatic patients, 
and this marker was also detected in the nasal lavage fluid of these 
patiens. 
Our results suggest that new sensitive biomarker panels for the 
clinical evaluation of allergic airway inflammation may be found 
using miRNA analysis and proteomics. Upper airways could be 
used as a surrogate of lower airways when assessing airway 
inflammation in asthma.
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